

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

Mark one

ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the fiscal year ended July 31, 2002

or

/ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 1-9974

ENZO BIOCHEM, INC.

(Exact name of Registrant as Specified in Its Charter)

New York

13-2866202

(State or Other jurisdiction
of Incorporation or Organization)

(I.R.S. Employer
Identification No.)

60 Executive Boulevard,
Farmingdale, New York

11735

(Address of Principal Executive Offices)

(Zip Code)

(631) 755-5500

(Registrant's telephone number,
including area code)

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, \$.01 par value

The New York Stock Exchange

(Title of Each Class)

(Name of Each Exchange on Which Registered)

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes

No /

Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]

The aggregate market value of the Common Stock held by nonaffiliates as
of October 8, 2002 was approximately \$336,089,000.

As of October 8, 2002, the Registrant had 28,459,800 shares of Common
Stock outstanding.

Part of Form 10-K

Document Incorporated by Reference

Part III - Items 11, 12 and 13

In the Company's Proxy Statement to be
filed with the Securities and Exchange
Commission no later than

Part IV - Certain exhibits listed in response to Item 14(a)(3) Prior filings made by the Company under the Securities Act of 1933 and the Securities Exchange Act of 1934

PART I

Item 1. Business

Overview

Enzo Biochem, Inc. (the "Company" or "Enzo") is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and also provides diagnostic services to the medical community. Since our formation in 1976, we have concentrated on developing enabling technologies for detecting and identifying genes and modifying gene expression. These technologies are generally applicable for the diagnosis of infectious and other diseases and form the basis for a portfolio of over 300 products marketed to the biomedical and pharmaceutical research markets. We are further using these technologies as a platform for our planned entry into the clinical diagnostics market. In addition, our work in gene analysis has led to our development of significant therapeutic product candidates, four of which are currently in clinical trials, and three are in preclinical studies. In the course of our research and development activities, we have built what we believe is a significant patent position (comprised of 38 issued U.S. patents, approximately 162 issued foreign patents and numerous pending applications worldwide) around our core technologies.

The business activities of the Company are performed by one of the Company's three wholly owned subsidiaries--Enzo Life Sciences, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. ("Enzo Life Sciences", "Enzo Therapeutics" and "Enzo Clinical Labs", respectively). These activities are: (1) research and development, manufacturing and marketing of biomedical research products and tools through Enzo Life Sciences and research and development of therapeutic products through Enzo Therapeutics, and (2) the operation of a clinical reference laboratory through Enzo Clinical Labs. For information relating to the Company's business segments, see Note 12 of the Notes to Consolidated Financial Statements.

The Company's primary sources of revenue have historically been from sales of research products and from clinical laboratory services. Revenues from research products are comprised of sales of products utilized in life science research. Revenues from the clinical laboratory service are comprised of fees for the services provided by the laboratories. For the fiscal years ended July 31, 2002 and 2001, respectively, approximately 48% and 33% of the Company's operating revenues were derived from product sales and approximately 52% and 67% were derived from clinical reference laboratory services.

Markets

Background

DNA is the source of biological information that governs the molecular mechanisms underlying life. This information is stored in the linear sequences of nucleotides that comprise DNA. The first draft of the sequence of the human genome, comprising over 30,000 genes, has been completed. The challenge for the next decade will be the determination of the function and relevance of each gene. This information will facilitate the understanding of biological mechanisms and how variations and mutations in such mechanisms result in disease, enabling more rapid and accurate detection of specific diseases and the development of new therapeutics to treat them.

Tools for biomedical and pharmaceutical research

There is an increasing demand by biomedical and pharmaceutical researchers for tools that both facilitate and accelerate the generation of biological information. In response to this demand, a variety of formats, or tools, have been developed that allow researchers to study biological pathways and to identify mutations in gene sequences and variations in gene expression levels that can lead to disease. These tools include DNA sequencing instruments, micro-arrays, biochips, micro-spheres, and microfluidic chips. Common among these formats is the need for reagents that allow the identification, quantification and characterization of specific genes or nucleic acid sequences.

We believe this market will grow rapidly as a result of:

- o research spending by academic, government and private organizations to determine the function and clinical relevance of the gene sequences identified by the Human Genome Project;

- o development of commercial applications based on information derived from this research; and
- o ongoing advancements in tools that accelerate these research and development activities.

3

Clinical diagnostics

Clinical diagnostics has been reported to be a greater than \$20 billion market in 2001. It is comprised of a broad range of tests such as clinical chemistry, microbiology, immunoassay, blood screening and cancer screening. Many of these tests employ traditional technologies, such as immunoassays and cell culture technologies, for the detection of diseases. Immunoassays use antibodies directed against a specific target, or antigen, to detect that antigen in a patient sample. Cell culturing uses nutrients media to grow, isolate and visually detect the presence of microorganisms.

There are several drawbacks to these technologies. Immunoassays do not allow for early detection of diseases because they require minimum levels of antigens to be produced by the microorganism for detection. These levels vary by microorganism, and the delay involved could be several days or several years, as seen in HIV/AIDS. Cell cultures are slow, labor intensive, and not amenable to all microorganisms. For example, gonorrhea and chlamydia are difficult to culture.

Gene-based diagnostics have many advantages over traditional technologies. Since gene-based diagnostics focus on the identification of diseases at the gene level, they can identify the presence of the disease at its earliest stage of manifestation in the body. These tests provide results more rapidly, are applicable to a broad spectrum of microorganisms and can easily be automated in a multiplex platform.

Several advances in technology are accelerating the adoption of gene-based diagnostics in clinical laboratories. These advances include high throughput automated formats that minimize labor costs, non-radioactive probes and reagents that are safe to handle, and amplification technologies that improve the sensitivity of such diagnostics.

According to industry sources, an estimated \$852 million was spent on gene-based diagnostics for clinical diagnosis in 2000. This market is projected to grow to \$1.83 billion in 2005 as a result of:

- o rising number of diagnostic tests being developed from discoveries in genome research;
- o advances in formats and other technologies that automate and accelerate gene-based diagnostic testing;
- o growing emphasis by the health-care industry on early diagnosis and treatment of disease; and
- o application of gene-based diagnostics as tools to match therapies to specific patient genetics, commonly referred to as pharmacogenomics.

Therapeutics

Most diseases are the consequence of the expression of foreign genes, such as those residing in viruses and pathogenic organisms, or the abnormal or unregulated expression of the body's own genes. In other cases, it is the failure to express a gene that causes the disease. Recent advancements in gene analysis have provided the information and tools necessary to develop drugs that intervene in the disease process at the gene level. For a broad spectrum of diseases, this approach can be more precise and effective than intervening in the downstream molecular processes of the disease. Therapies targeting genetic processes are called gene medicines. There are two fundamental approaches to gene medicines, synthetic and genetic.

Synthetic gene medicine involves the administration of synthetic nucleic acid sequences called "oligos" that are designed to bind to, and thus deactivate, RNA produced by a gene. To date, this approach has demonstrated limited success. Since a single cell may contain thousands of strands of RNA, large amounts of oligos are necessary to shut down the production of unwanted proteins. Also, since oligos are synthetic, they are quickly metabolized or eliminated by the body. As a result, large quantities of oligos must be delivered in multiple treatments, which can be both toxic to the body as well as costly.

Genetic medicine, or gene therapies involve the insertion of a gene

into a cell. The inserted gene biologically manufactures the therapy on an ongoing basis. This gene may be inserted to enable a beneficial effect or to disable a pathological mechanism within the cell. For example, the gene may be inserted to replace a missing or malfunctioning gene responsible for synthesizing an essential protein. On the other hand, a gene coding for a molecule to deactivate either an overactive gene or a gene producing an unwanted protein may be inserted. As a permanent addition to the cellular DNA, the inserted gene produces RNA and/or proteins where needed.

4

A major challenge in designing gene therapy medicines has been the efficient and safe delivery of the gene to the appropriate target cell. Gene delivery is often accomplished using a delivery vehicle known as a vector. A critical quality of the vector is its ability to bind to the target cell and effectively deliver, or transduce, the gene into the cell. It is also critical that the DNA of the vector not produce proteins or antigens that can trigger an adverse immune response.

Strategy

Our objective is to be the leading developer and provider of medicines, as well as the tools and diagnostics used to study and detect disease at the molecular level. There can be no assurances that our objective will be met. Key elements of our strategy include:

Apply our innovative technology to the infectious disease market

Our core technologies have broad diagnostic and therapeutic applications. We have initially focused our efforts on the infectious disease market. Infectious diseases are among the largest contributors of healthcare costs worldwide. Generally, there are no long-term effective treatments for viral pathogens as there are for bacterial pathogens. We have developed novel technologies we believe can serve as enabling platforms for developing medicines that genetically target and inhibit viral functions, as well as regulate immune response. In addition to such therapeutic products, we have capitalized on our nucleic acid labeling, amplification and detection technologies to develop diagnostic and monitoring tests for infectious agents.

Maximize our resources by collaborating with others in research and commercialization activities

We enter into research collaborations with leading academic and other research centers to augment our core expertise on specific programs. We have research collaborations with, among others, Hadassah University Hospital in Jerusalem, Israel regarding immune regulation and Cornell University regarding the application of our genetic antisense technology to HIV. Similarly, we seek to fully exploit the commercial value of our technology by partnering with for-profit enterprises in areas outside our primary commercial interests.

Apply our biomedical research products to the clinical diagnostics market

We intend to apply our gene-based tests to the clinical diagnostics market. We currently offer over 25 gene-based tests for the research market, for the identification of such viruses as Human Papillomavirus, Cytomegalovirus, and Epstein-Barr virus. We also have an extensive library of probes for the detection of various diseases. We have developed a standardized testing format that permits multiple diagnoses to be performed on the same specimen and are in discussions with third parties to develop instrumentation for this purpose.

Leverage marketing and distribution infrastructure of leading life sciences companies

In addition to our direct sales, we distribute our research products through leading producers of gene analysis formats and other life sciences companies. By partnering with these industry leaders, we are able to leverage their established marketing and distribution infrastructure to expand the market for our products. We have distribution agreements with, among others, Roche Diagnostic Systems, Amersham PLC, Perkin-Elmer Life Sciences and Affymetrix.

Expanding and protecting our intellectual property estate

Since our inception, we have followed a strategy to create a broad encompassing patent position in the life sciences and therapeutics areas. We have made obtaining patent protection a central strategic policy, both with respect to our proprietary platform technologies and products, as well as broadly in the areas of our research activities.

Core Technologies

We have developed a portfolio of proprietary technologies with a

variety of research, diagnostic and therapeutic applications.

Gene analysis technology

All gene-based testing is premised on the knowledge that DNA forms a double helix comprised of two complementary strands that match and bind to each other. If a complementary piece of DNA (a probe) is introduced into a sample containing its matching DNA, it will bind to, or hybridize, to form a double helix with that DNA. Gene-based testing is carried out by:

5

- o amplification of the target DNA sequence (a process that is essential for the detection of very small amounts of nucleic acid);
- o labeling the probe with a marker that generates a detectable signal upon hybridization;
- o addition of the probe to the sample containing the DNA; and
- o binding or hybridization of the probe to the target DNA sequence, if present, to generate a detectable signal.

We have developed a broad technology base for the labeling, detection, amplification and formatting of nucleic acids for gene analysis. We believe we have a significant proprietary position in these fields.

Non-radioactive labeling and detection. Traditionally, nucleic acid probes were labeled with radioactive isotopes. However, radioactively labeled probes have a number of shortcomings. They are unstable and consequently have a limited shelf life. They are potentially hazardous, resulting in restrictive licensing requirements and safety precautions for preparation, use and disposal. Finally, radioactive components are expensive. Our technologies permit gene analysis without the problems associated with radioactively labeled probes and are adaptable to a wide variety of formats.

Formats. There are various processes, or formats, for performing probe-based tests. In certain formats, the probe is introduced to a target sample affixed to a solid matrix; in others the probe is combined with the sample in solution (homogeneous assay). Solid matrix assays include: in situ assays in which the probe reaction takes place directly on a microscope slide; dot blot assays in which the target DNA is fixed to a membrane; and microplate and microarray assays in which the DNA is fixed on a solid surface, and the reaction can be quantified by instrumentation.

Amplification. In the early stages of infection, a pathogen may be present in very small amounts and consequently may be difficult to detect. Using DNA amplification, samples can be treated to cause a pathogen's DNA to be replicated, or amplified, to detectable levels. We have developed a proprietary amplification process for multicopy production of nucleic acid, as well as proprietary techniques for amplifying the signals of our probes to further improve sensitivity. Our amplification technologies are particularly useful for the early detection of very small amounts of target DNA and, unlike PCR, (currently the most commonly used method of amplification,) we have developed isothermal amplification procedures that can be performed at constant temperatures and thus do not require expensive heating and cooling systems or specialized heat-resistant enzymes.

Therapeutic Technology Platforms

We have developed proprietary technologies in the areas of genetic antisense (antisense RNA) and immune regulation that we are using as a platform for a portfolio of novel therapeutics.

Gene Regulation Technology. We are pursuing a novel approach to gene regulation known as genetic antisense or antisense RNA. Our technology involves the introduction into cellular DNA of a gene that codes for an RNA molecule that binds to, and thus deactivates, RNA produced by a specific gene. To deliver our antisense gene to the target cell, we have developed proprietary vector technology. Our vector technology has the following three strengths:

- o Efficient transduction. A principal problem to date of most gene therapy programs has been inefficient transduction, or an unacceptably low rate of delivery of operating genes to the target cells. We have achieved transduction rates significantly higher than those reported by other researchers.

- o Immunologically "Quiet." Transduced cells often produce non-essential proteins that trigger an immune response, causing such cells to be cleared from the body before they can produce a therapeutic effect. Cells transduced with our Stealth Vectors(TM) have not expressed extraneous proteins.

o "Smart" Vectors. We incorporate into the surface of our vectors proteins that have an affinity for the surface of the cell types intended to be transduced. By including this targeting mechanism, we create in essence "smart" vectors that preferentially transduce the intended cell type. This may ultimately permit us to develop a genetic antisense product that is administered directly to the patient.

We believe that our vector technology has broad applicability in the field of gene medicine. This can be attributed to the following properties of our construct:

- o the viral promoters are inactivated;
- o insertional gene activation is prevented - a major safety factor;
- o chromosomal integration;
- o nuclear localization

6

Immune Regulation Technology. We have developed a novel therapeutic approach based on immune regulation. Our immune regulation technology seeks to control an individual's immune response to a specific antigen in the body. An antigen is a substance that the body perceives is foreign and, consequently, against which the body mounts an immune response. We are developing our technology to treat immune-mediated diseases, infectious diseases and complications arising from transplantation. Our technology utilizes oral administration of known proteins to regulate the subject's immune response against the antigen. Specific formulations of the protein are administered orally to the patient according to precise dosing protocols.

We have filed patent applications relating to this technology, as well as to our therapeutics and protocols under development, relating to areas of infectious diseases and immunological adjustments and enhancements characteristic of this reaction. We are applying our expertise in immune regulation to develop proprietary therapeutics for the treatment of a variety of diseases, including HIV-1 infection, chronic active hepatitis caused by HBV and HCV infection, graft versus host disease and inflammatory bowel disease, including Crohn's Disease and ulcerative colitis.

Products and Services

We are applying our core technologies to develop novel therapeutics as well as research tools for the life sciences and clinical diagnostics markets. In addition, we provide clinical laboratory services to physicians and other health care providers in the greater New York area.

Research and Diagnostic Products

We are a leading developer and marketer of novel research tools for gene analysis. We manufacture over 300 products that may be sold individually or combined in a kit to meet the specific needs of the researcher. We market these products to biomedical and pharmaceutical firms worldwide. We have summarized our products into the following major categories:

Pre-Formatted In Situ Kits. Our pre-formatted in situ kits include all of the components necessary to identify or detect a gene in a cell or tissue on a glass slide. These components include specific labeled non-radioactive nucleic acid probes on a glass slide, signaling reagents and buffers. We offer probes that will detect a variety of infectious agents, such as human papillomavirus (HPV), hepatitis B (HBV), cytomegalovirus (CMV) and chlamydia. We market these kits under the PathoGene(R) brand name. These kits target the pathology market.

Pre-Formatted Microplate Kits. Our pre-formatted microplate kits include all of the components necessary to identify or detect a gene in a microplate assay. These components include specific labeled non-radioactive nucleic acid probes on a microplate, signaling reagents and buffers. We offer probes that will detect a variety of infectious agents, such as HIV, hepatitis B (HBV) and tuberculosis. This microplate format enables the development of probe-based tests that can be readily automated and quantified.

Membrane Kits. Our membrane kits include all of the reagents and buffers necessary to perform a gene analysis on a membrane. The researcher will supply the probe required for their individual needs. Membrane technology is broadly used in life sciences research. We market these kits under the MaxSense(R) brand name.

Labeled Probes. We have developed a line of non-radioactive nucleic acid probes that have been chemically-labeled to allow detection of infectious agents. We offer labeled probes that can detect such infectious agents as adenovirus, hepatitis B (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV) and chlamydia, as well as certain oncogenes. These probes can be used in hybridization and detection assays in the format chosen by the researcher. These probes are broadly sold into the life sciences research market under the BioProbe(R) brand name.

Labeling and Signaling Reagents. We have developed an extensive line of labeling and signaling systems and reagents for the life sciences research market. These reagents can be used by researchers to identify and detect genes on any particular format. We are in the process of expanding this product line to increase our penetration in this growing market.

Therapeutic Development Programs

We have a number of therapeutic products in various stages of development that are based on our proprietary genetic antisense and immune regulation technologies. Our therapeutic programs are described below.

Human Immunodeficiency Virus (HIV-1). We are developing complementary HIV-1 therapeutics utilizing both our genetic antisense and immune regulation technologies.

7

HIV-1 is a human pathogenic virus. After infection it runs a slow course in which certain of the cells in the immune system (CD4+ cells) progressively disappear from the body. This results in a state in which the infected person can no longer mount an immune response. This loss of immune responsiveness is the cause of the complex of diseases known as AIDS and ultimately of death.

According to estimates by the Joint United Nations Programme on HIV/AIDS, over 40 million people are living with HIV/AIDS worldwide. At present, two classes of products have received FDA marketing approval for HIV-1 infection: reverse transcriptase inhibitors and protease inhibitors. These drugs are typically used in combination and may require more than a dozen tablets to be taken at specific times each day. The cost for treatment of HIV infected individuals, once the disease has progressed to AIDS, is estimated to exceed \$38,000 per person annually.

While combination therapy slows the progression of disease, it is not a cure. HIV's rapid rate of mutation results in the development of viral strains that no longer respond to these medications. This problem is often exacerbated by interruptions in dosing as non-compliance is common in patients on combination therapies. Moreover, currently approved drugs produce toxic side-effects in many patients, affecting a variety of organs and tissues, including the peripheral nervous system and gastrointestinal tract, which side-effects also often result in patients interrupting or discontinuing therapy.

HGTV43(TM) gene medicine. HGTV43 Enzo's proprietary StealthVector(TM) carrying anti-HIV-1 antisense RNA genes directed against the genes responsible for viral replication. HGTV43 is designed to deliver the antisense genes to targeted blood cells of subjects infected with HIV-1. These genes are incorporated into the DNA of the blood cells, and subsequent production of the antisense RNA prevents replication of the virus, providing resistance to the virus.

Preclinical in vitro studies, performed in conjunction with our academic collaborators demonstrated resistance to HIV-1 in human immune cells into which the antisense genes had been inserted. Our Phase I clinical trial of the HIV-1 gene medicine is in the follow up phase with five evaluable subjects. In this study, white blood cell precursors, known as stem cells, were collected from the subjects. These stem cells were then treated with HGTV43 ex vivo and infused into the subject. Results of the trial have shown that all subjects tolerated the procedure and that anti-HIV-1 antisense RNA continued to be expressed in the subjects' circulating white blood cells for as long as 24 months to date.

- o all subjects tolerated the procedure;
- o anti HIV-1 antisense RNA was detected in the circulation of subjects, for as long as 24 months thus far;
- o purified CD4+ cells from all five evaluable subjects were tested for the presence of anti HIV-1 antisense RNA and these cells contained the antisense RNA;
- o CD34+ cells from the bone marrow of all subjects were tested for the presence of anti HIV-1 antisense RNA between 6 months and 20 months after infusion and these cells all contained the antisense RNA.

Based on these Phase I trial results demonstrating long-term survival and functioning of antisense RNA in white blood cells and in CD4+ cells we are preparing for the next phase of the study in which we will test strategies to increase the percentage of CD4+ cells that contain the anti-HIV-1 antisense genes.

One arm of the next phase of clinical trials is expected to be conducted at New York Presbyterian Hospital-Cornell Medical Center. Enzo's protocol for this phase of the study was successfully presented to and approved by the National Institutes of Health Recombinant DNA Advisory Committee (RAC) and Cornell's Institutional Review Board "IRB". The Cornell site will focus on a strategy to increase the percentage of engineered CD4+ cells by using a combination of radiation and immune conditioning. We anticipate beginning expanded studies of the trial at additional sites.

Immune regulation product. We are developing a complementary approach to treat HIV infection and the related autoimmune aspect of the disease. It is suggested that this autoimmune aspect may lead to depletion of CD4+ cells. This therapeutic approach utilizes our immune regulation technology to adjust and enhance the body's immune response to the virus. This treatment, consisting of oral administration of an HIV protein, is designed to reduce or eliminate the autoimmune aspect of HIV infection. In addition, it enhances the antiviral immune response, which may increase the population of CD4+ cells in the patient. This program is currently in pre-clinical development.

Hepatitis B (HBV). We are developing HBV therapeutics utilizing both our proprietary immune regulation technologies.

HBV is a viral pathogen that can lead to a condition in which the body destroys its own liver cells through an immune response. This condition is commonly referred to as chronic active hepatitis. According to the latest figures published by the World Health Organization, approximately 2 billion people are infected by HBV, in whom an estimated 350 million are chronically infected and therefore at risk of death from liver disease.

8

Chronic active hepatitis is generally treated with interferon or lamivudine. Both of these drugs, however, are toxic, and many patients cannot tolerate their side effects. These treatments have a limited success rate (5-15%).

EHT899 immune regulation product. EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

In a clinical trial, conducted at the Liver Unit of Hadassah-Hebrew University Medical Center, in Jerusalem, Israel, a formulation of EHT899 was administered orally to a total of 42 subjects with chronic active hepatitis. Subjects received the medication three times a week for 20 - 30 weeks and were followed for an additional 20 weeks. Results of the trial have shown that:

- o The drug was well tolerated in all subjects;
- o 46% of subjects showed a decrease in HBV viral load and improvement in liver function tests;
- o 33% of subjects showed a decrease in inflammation seen on liver biopsy;

Based on these results, the Company is preparing to begin a multi-center Phase II random-label double blind clinical study.

Preclinical animal studies with EHT899 showed that this medication was able to achieve complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice. These studies may have significant potential application for treatment of liver and other cancers in humans.

Hepatitis C (HCV EHC18). We are using our proprietary immune regulation technology in the development of a treatment for HCV. This disease affects approximately 170 million people worldwide, including 3.9 million in the U.S., of which approximately 69%, or 2.7 million, are chronically infected, according to the National Center for Infectious Diseases. Approximately 30,000 new infections are recorded each year in the U.S. About 85% of people infected with HCV are reported to develop chronic hepatitis, and about 20% develop cirrhosis, an incurable disease, with approximately half of these cases progressing to end-stage liver disease, including liver cancer. It has been predicted that HCV-related deaths in the U.S. may soon overtake the number of AIDS-related deaths in the U.S.

The Phase I clinical trial conducted by physicians at the Liver Unit of Hadassah University Medical Center in Jerusalem, Israel has met its safety endpoints. Enzo is currently looking to the next level of study.

Inflammatory bowel diseases. We are applying our immune regulation

technology to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's Disease. According to the Inflammatory Bowel Disease Foundation, approximately one million persons in the United States suffer from IBD. Although the cause of these disorders remains unknown, various features suggest immune system involvement in their pathogenesis.

There is currently no effective treatment for these diseases. Subjects are managed during short-term episodes through the use of anti-inflammatory medications, or immunosuppressants, that provide symptomatic relief over short periods of time, but do not provide a cure. These drugs are all based on a generalized suppression of the immune response and are non-specific. As such, they have considerable side effects and cannot be used for long periods of time because of their inherent toxicity.

Enzo is currently conducting a Phase I clinical trial to test an innovative immune regulation medicine for treatment of Crohn's Disease. The clinical study is based on successful preclinical results achieved in an animal model system. The preclinical study results showed that when laboratory animals with experimentally induced colitis were given specific proteins by oral administration, a remission of the condition was seen. The experimental animals exhibited a marked amelioration of the symptoms, including significant reduction in tissue inflammation, as well as a decrease in the levels of gamma interferon in the serum, both indicative of remission.

Graft versus Host Disease. We are applying our immune regulation technology to treat graft versus host disease. Graft versus Host Disease (GvHD) is a major complication of bone marrow and stem cell transplantation accounting for many of the failures of these transplant procedures. GvHD is characterized by an immune response mounted by the immune cells within the engrafted tissue against the recipient that leads to a wasting syndrome and occasionally death. It is estimated that there are only 15,000 bone marrow transplants performed annually worldwide due, in part, to GvHD. It is assumed that the elimination of GvHD would lead to a dramatic rise in the number of these procedures. GvHD is currently treated by immunosuppressant drugs, which are toxic and only reduce the extent of the wasting reaction.

9

We are conducting pre-clinical and animal studies at Hadassah University Hospital. The results of these studies have demonstrated that our immune regulation technology could be effective in treating GvHD. We have developed clinical protocols and, subject to regulatory approval, expect to commence human trials during 2003.

Research product revenue from one major distributor represented approximately 23% and 12% of the consolidated revenues in fiscal 2002 and 2001, respectively, under a non-exclusive distribution and supply agreement. At July 31, 2002 and 2001, 18% and 5% respectively, of the Company's net accounts receivable relate to amounts due from the one major distributor.

In the fiscal years ended July 31, 2002, 2001 and 2000, the Company incurred costs of \$6,179,000, \$6,081,000 and \$5,431,000, respectively, for research and development activities.

Clinical Laboratory Services

We operate a regional clinical reference laboratory that offers full diagnostic services to the greater New York medical community. The services we provide include chemistry, blood tests, cytology studies, tissue pathology, hormone studies and screening for cancer and infectious diseases. We provide these services primarily to physicians, as well as to clinics and other clinical laboratories.

The Company offers over 2,000 different routine and esoteric clinical laboratory tests or procedures. These tests are frequently used in general patient care by physicians to establish or support a diagnosis, to monitor treatment or medication, or search for an otherwise undiagnosed condition. These routine and esoteric procedures are most often used by practicing physicians in their outpatient office practices.

We operate a clinical reference laboratory on Long Island and eighteen satellite patient service centers in the greater New York area. Patient service centers collect the specimens as requested by physicians. The specimens are sent through our in-house courier system to our Long Island laboratory facility for testing. We also operate a STAT laboratory in Manhattan. A "STAT" lab is a laboratory that has the ability to perform certain routine tests quickly and report results to the physician immediately.

Patient specimens are delivered to our facilities accompanied by a test request form. These forms, which are completed by the physician, indicate the tests to be performed and provide the necessary billing information. Once this information is entered into the computer system, the tests are performed and the results are entered primarily through a computer interface or manually. Most

routine testing is completed by early the next morning, and test results are printed and prepared for distribution. Some physicians have local printer capability and have reports printed out directly in their offices. Physicians who request that they be called with a result are so notified in the morning.

We utilize our clinical reference laboratory to evaluate and demonstrate the benefits of our internally developed gene-based diagnostic products. In addition, our laboratory is currently performing gene-based tests in support of our HIV-1 clinical studies.

Approximately 68% at July 31, 2002 and 82% at July 31, 2001, of the Company's net accounts receivable relates to its clinical reference laboratory business, which operates in the New York Metropolitan area. The Company believes that the concentration of credit risk with respect to accounts receivable is limited due to the diversity of the Company's client base. However, the Company provides services to certain patients covered by various third-party payors, including the Federal Medicare program. Revenue, net of contractual allowances, from direct billings under the Federal Medicare program during July 31, 2002 was approximately 6% of the Company's total revenue.

Research & Development

Our principal research and development efforts are directed toward expanding our research and diagnostic product lines, as well as developing innovative new therapeutic products to meet unmet market needs. We have developed our core research expertise in genomics through 20 years of dedicated focus in this area. We conduct our research and other product development efforts through internal research and collaborative relationships.

Internal Research Programs

Our internal research and development activities, centered in Farmingdale, New York, are performed by a staff of approximately 30 professionals and scientists. Our product development programs incorporate various scientific areas of expertise, including recombinant DNA, monoclonal antibody development, enzymology, microbiology, biochemistry, molecular biology, organic chemistry, and fermentation. In addition, we continuously review in-licensing opportunities in connection with new technology.

10

External Research Collaborations

We have and continue to explore collaborative relationships with prominent companies and leading-edge research institutions in order to maximize the application of our technology in areas where we believe such relationship will benefit the development of our technology.

Sales and Marketing

Our sales and marketing strategy is to sell our products through two distinct channels: (i) direct sales to end-users; and (ii) supply agreements with manufacturers and distributors.

Direct Sales and Marketing Effort

We internally market our products through our catalogue, direct field sales and telemarketing, as well as through our e-commerce web site. We maintain a team of professionals to perform direct field sales and telemarketing activities. Our worldwide marketing efforts also consist of advertisements in major scientific journals; direct mailings to researchers; presentations at scientific seminars; and exhibitions at scientific meetings.

Supply and Distribution Arrangements

We also distribute our products through leading life sciences companies. These companies include manufacturers of instruments for gene analysis, where our reagents are critical for the identification and detection of genes and nucleic acid sequences. Through these arrangements, we are able to leverage the established marketing and distribution infrastructure of these companies. We have distribution agreements with, among other companies:

- o Affymetrix;
- o Amersham PLC;
- o Dako;
- o Perkin Elmer Life Sciences;
- o Ortho Diagnostics;
- o Roche Diagnostics;
- o VWR International.

Competition

We compete with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. Competition in our industry is intense and is expected to increase. Many of these companies are performing research in the same areas as we are. These competitors have more significant financial resources than we do. The primary competitive factors in our industry are the ability to create scientifically advanced technology, successfully develop and commercialize products on a timely basis, establish and maintain intellectual property rights and attract and retain a breadth and depth of human resources.

Our clinical laboratory services business competes with numerous national and local entities, some of which are larger and have greater financial resources than we do. Our laboratory competes primarily on the basis of the quality and specialized nature of its testing, reporting and information services, its reputation in the medical community, the pricing of its services, its reliability and speed in performing diagnostic tests, and its ability to employ qualified laboratory personnel.

Intellectual Property

We consider our intellectual property program to be a key asset and a major strategic component to the execution of our business strategy. Our core technology platforms are supported by a broad portfolio of issued patents and pending patent applications. Our policy is to seek patent protection for our core technology platforms, as well as for ancillary technologies that support these platforms and provide a competitive advantage.

At the end of fiscal 2002 we owned or licensed 38 U.S. and approximately 162 foreign patents relating to products, methods and procedures resulting from our internal or sponsored research projects. Patents relating to the BioProbe(R) nucleic acid probe system have issued in the U.S. and Europe. We cannot assure, however, that patents will be issued on pending applications or that any issued patents will have commercial benefit. We do not intend to rely on patent protection as the sole basis for protecting our proprietary technology. We also rely on our trade secrets and continuing technological innovation. We require each of our employees to sign a confidentiality agreement that prohibits the employee from disclosing any confidential information about us, including our technology or trade secrets.

In some instances, we may enter into royalty agreements with collaborating research parties in consideration for the commercial use by us of the developments of their joint research. In other instances a patent might be obtained by the collaborating party, but we receive the license to use the patented subject matter. In such cases, we will seek to secure exclusive licenses. In other instances, we might have an obligation to pay royalties to, or reach a royalty arrangement with, a third party in consideration of our use of developments of such third party. We have an exclusive licensing agreement with Yale for the technology used in nucleic acid probe products. That agreement covers licensed patents owned by Yale and licensed to us for the life of the patents, which expire not earlier than 2004. The Research Foundation of the State University of New York has granted us the exclusive rights to a genetic engineering technology using antisense nucleic acid control methodologies.

Regulation of Pharmaceutical Products

New drugs and biological drug products are subject to regulation under the Federal Food, Drug and Cosmetic Act, and biological products are also regulated under the Public Health Service Act. We believe that products developed by us or our collaborators will be regulated either as biological products or as new drugs. Both statutes and the regulations promulgated thereunder govern, among other things, the testing, licensing, manufacturing, marketing, distributing, safety, and efficacy requirements, labeling, storage, exporting, record keeping, advertising and other promotional practices involving biologics or new drugs, as the case may be. FDA review or approval or other clearances must be obtained before clinical testing, and before manufacturing and marketing, of biologics and drugs. At the FDA, the Center for Biological Evaluation and Research ("CBER") is responsible for the regulation of biological drugs and the Center for Drug Evaluation and Research ("CDER") is responsible for the regulation of non-biological drugs. Biological drugs are licensed and other drugs are approved before commercialization.

Any gene medicine products that we develop will require regulatory review before clinical trials, and additional regulatory clearances before commercialization. New human gene medicine products, as therapeutics, are subject to regulation by the FDA and comparable agencies in other countries. The precise regulatory requirements with which we will have to comply are uncertain at this time because of the novelty of the human gene therapies currently under development. Each protocol is currently reviewed by the FDA on a case-by-case basis. The FDA has published "Points to Consider" guidance documents with respect to the development of gene medicine protocols. The National Institutes

of Health ("NIH") is also involved in the oversight of gene therapies and the FDA has required compliance with certain NIH requirements.

Obtaining FDA approval has historically been a costly and time-consuming process. Generally, to gain FDA approval, a developer first must conduct pre-clinical studies in the laboratory evaluating product chemistry, formulation and stability and, if appropriate, in animal model systems, to gain preliminary information on safety and efficacy. Pre-clinical safety tests must be conducted by laboratories that comply with FDA regulations governing Good Laboratory Practices. The results of those studies are submitted with information characterizing the product and its manufacturing process and controls as a part of an investigational new drug ("IND") application, which the FDA must review and declare effective before human clinical trials of an investigational drug can start. The IND application includes a detailed description of the clinical investigations to be undertaken in addition to other pertinent information about the product, including descriptions of any previous human experience and the company's future plans for studying the drug.

In order to commercialize any products, we (as the sponsor) file an IND and will be responsible for initiating and overseeing the clinical studies to demonstrate the safety and efficacy necessary to obtain FDA marketing approval of any such products. For INDs that we sponsor, we will be required to select qualified clinical sites (usually physicians affiliated with medical institutions) to supervise the administration of the products, and ensure that the investigations are conducted and monitored in accordance with FDA regulations and the general investigational plan and protocols contained in the IND. Each clinical study is reviewed and approved by an Institutional Review Board (IRB). The IRB will consider, among other things, ethical factors and the safety of human subjects. Clinical trials are normally conducted in three phases, although the phases might overlap. Phase I trials, concerned primarily with the safety and tolerance of the drug, and its pharmacokinetics (or how it behaves in the body including its absorption and distribution) involve fewer than 100 subjects. Phase II trials normally involve a few hundred patients and are designed primarily to demonstrate preliminary effectiveness and the most suitable dose or exposure level for treating or diagnosing the disease or condition for which the drug is intended, although short-term side effects and risks in people whose health is impaired may also be examined. Phase III trials are expanded, adequate and well-controlled clinical trials with larger numbers of patients and are intended to gather the additional information for proper dosage and labeling of the drug. Clinical trials generally take two to five years, but the period may vary. Certain regulations promulgated by the FDA may shorten the time periods and reduce the number of patients required to be tested in the case of certain life-threatening diseases, which lack available alternative treatments.

12

The FDA receives reports on the progress of each phase of clinical testing, and it may require the modification, suspension or termination of clinical trials if an unwarranted risk is presented to patients. Human gene medicine products are a new category of therapeutics. We cannot assure the length of the clinical trial period, the number of patients that the FDA will require to be enrolled in the clinical trials in order to establish the safety, purity and potency of human gene medicine products, or that the clinical and other data generated will be acceptable to the FDA to support marketing approval.

After completion of clinical trials of a new product, FDA marketing approval must be obtained before the product can be sold in the United States. If the product is regulated as a new biologic, CBER requires the submission and approval of a Biologics License Application (BLA) before commercial marketing of the Biologic. If the product is classified as a new drug, we must file a New Drug Application ("NDA") with CDER and receive approval before commercial marketing of the drug. The NDA or BLA must include results of product development, pre-clinical studies and clinical trials. The testing and approval processes require substantial time and effort and we cannot assure that any approval will be granted on a timely basis, if at all. The median time to obtain new product approvals after submission to the FDA is approximately 12 months. If questions arise during the FDA review process, approval can take longer. Before completing its review, the FDA may seek guidance from an Advisory Committee of outside experts at a public or closed meeting. While the advice of these committees is not binding on the FDA, it is often followed. Notwithstanding the submission of relevant data, the FDA might ultimately decide that the NDA or BLA does not satisfy its regulatory criteria for approval and, thus, reject the application, refuse to approve it, or require additional clinical, preclinical or chemistry studies. Even after FDA regulatory approval or licensure, a marketed drug product is subject to continual review by the FDA. In addition, if previously unknown problems are discovered or we fail to comply with the applicable regulatory requirements, we might be restricted from marketing a product, we might be required to withdraw the product from the market, and we might possibly become subject to seizures, injunctions, voluntary recalls, or civil, monetary or criminal sanctions. In addition, the FDA may condition marketing approval on the conduct of specific post-marketing studies to further evaluate safety and effectiveness.

For commercialization of our biological or other drug products, the manufacturing processes described in our NDA or BLA must receive FDA approval and the manufacturing facility must successfully pass an inspection prior to approval or licensure of the product for sale within the United States. The pre-approval inspection assesses whether, for example, the facility complies with the FDA's current good manufacturing practices (cGMP) regulations. These regulations elaborate testing, control, documentation, personnel, record keeping and other quality assurance procedure requirements that must be met. Once the FDA approves our biological or other drug products for marketing, we must continue to comply with the cGMP regulations. The FDA periodically inspects biological and other drug manufacturing facilities to ensure compliance with applicable cGMP requirements. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product or voluntary recall of a product.

If a developer obtains designations by the FDA of a biologic or other drug as an "orphan" for a particular use, the developer may request grants from the federal government to defray the costs of qualified testing expenses in connection with the development of such drug. Orphan drug designation is possible for drugs for rare diseases, including many genetic diseases, which means the drug is for a disease that has a prevalence of less than 200,000 patients in the United States. The first applicant who receives an orphan drug designation and who obtains approval of a marketing application for such drug acquires the exclusive marketing rights to that drug for that use for a period of seven years unless the subsequent drug can be shown to be clinically superior. Accordingly, no other company would be allowed to market an identical orphan drug with the same active ingredient for the use approved by the FDA for seven years after the approval.

Regulation of Diagnostics

The diagnostic products that are developed by us or our collaborators are likely to be regulated by the FDA as medical devices. Unless an exemption applies, medical devices must receive either "510(k) clearance" or pre-market approval ("PMA") from the FDA before marketing them in the United States. The FDA's 510(k) clearance process usually takes from four to 12 months, but it can last longer. The process of obtaining PMA approval is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer. We cannot be sure that 510(k) clearance or PMA approval will ever be obtained for any product we propose to market.

The FDA decides whether a device must undergo either the 510(k) clearance or PMA approval process based upon statutory criteria. These criteria include the level of risk that the agency perceives is associated with the device and a determination whether the product is a type of device that is similar to devices that are already legally marketed. Devices deemed to pose relatively less risk are placed in either class I or II, which requires the manufacturer to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. The premarket notification must demonstrate that the proposed device is "substantially equivalent" in intended use and in safety and effectiveness to a legally marketed "predicate device" that is either in class I, class II, or is a "preamendment" class III device (i.e., one that was in commercial distribution before May 28, 1976) for which the FDA has not yet called for submission of a PMA application.

13

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require a PMA approval. The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer's decision not to seek a new 510(k) clearance, the agency may retroactively require the manufacturer to seek 510(k) clearance or PMA approval. The FDA also can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained.

Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or deemed not substantially equivalent to a legally marketed class I or class II predicate device, or to a preamendment class III device for which PMAs have not been called, are placed in class III. Such devices are required to undergo the PMA approval process in which the manufacturer must prove the safety and effectiveness of the device to the FDA's satisfaction. A PMA application must provide extensive preclinical and clinical trial data and also information about the device and its components regarding, among other things, device design, manufacturing and labeling. After approval of a PMA, a new PMA or PMA supplement is required in the event of a modification to the device, its labeling or its manufacturing process.

Although clinical investigations of most devices are subject to the

investigational device exemption ("IDE") requirements, clinical investigations of in vitro diagnostic ("IVDs") tests are exempt from the IDE requirements, including the need to obtain the FDA's prior approval, provided the testing is noninvasive, does not require an invasive sampling procedure that presents a significant risk, does not introduce energy into the subject, and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition, the IVD must be labeled for Research Use Only (RUO) or Investigational Use Only (IUO), and distribution controls must be established to assure that IVDs distributed for research or investigation are used only for those purposes. The FDA expressed its intent to exercise heightened enforcement with respect to IUO and RUO devices improperly commercialized prior to receipt of FDA clearance or approval.

We have developed products that we currently distribute in the United States on a RUO basis. There can be no assurance that the FDA would agree that our distribution of these products meets the requirements for RUO distribution. Furthermore, failure of us or recipients of our RUO products to comply with the regulatory limitations on the distribution and use of such devices could result in enforcement action by the FDA, including the imposition of restrictions on our distribution of these products.

Any devices that we manufacture or distribute will be subject to a host of regulatory requirements, including the Quality System Regulation (which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures), the Medical Device Reporting regulation (which requires that manufacturers report to the FDA certain types of adverse events involving their products), labeling regulations, and the FDA's general prohibition against promoting products for unapproved or "off label" uses. Class II devices also can have special controls such as performance standards, postmarket surveillance, patient registries, and FDA guidelines that do not apply to class I devices. Unanticipated changes in existing regulatory requirements or adoption of new requirements could hurt our business, financial condition and results of operations.

We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to comply, the agency can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such as fines, injunction, civil penalties, recall or seizure of our products, the issuance of public notices or warnings, operating restrictions, partial suspension or total shutdown of production, refusal of our requests for 510(k) clearance or PMA approval of new products, withdrawal of 510(k) clearance or PMA approvals already granted, and criminal prosecution.

The FDA also has the authority to request repair, replacement or refund of the cost of any medical device manufactured or distributed by us. Our failure to comply with applicable requirements could lead to an enforcement action that may have an adverse effect on our financial condition and results of operations.

Unanticipated changes in existing regulatory requirements, our failure to comply with such requirements or adoption of new requirements could have a material adverse effect on us.

We have employees to expedite the preparation and filing of documentation necessary for FDA clearances and approvals, patent issuances and licensing agreements. We have received clearance from the FDA to market five of our in vitro diagnostic products.

We cannot assure you that future clinical diagnostic products developed by us or our collaborators will not be required to be reviewed by FDA under the more expensive and time consuming pre-market approval process.

Clinical Laboratory Regulations

The clinical laboratory industry is subject to significant governmental regulation at the Federal, state, and local levels. Under the Clinical Laboratory Improvement Act of 1967 and the Clinical Laboratory Improvement Amendments of 1988 (collectively, as amended, "CLIA"), our clinical laboratories must be certified by the Federal government, or exempt from Federal certification, as discussed below. Many clinical laboratories also must meet other governmental standards, undergo proficiency testing, and are subject to inspection. Clinical laboratory certificates or licenses are also required by various state and local laws.

CLIA places all tests into one of three categories of complexity (waived, moderate complexity and high complexity) and establishes varying requirements depending upon the complexity category of the test performed. A laboratory that performs high complexity tests must meet more stringent requirements than a laboratory that performs only moderate complexity tests, while those that perform only waived tests may apply for a certificate of waiver from most of the requirements of CLIA. Our facility is certified to perform

highly complex tests. In general, the HHS regulations require laboratories that perform high or moderate complexity tests to implement systems that ensure the accurate performance and reporting of test results, establish quality control and quality assurance systems, ensure hiring of personnel that meet specified standards, engage in proficiency testing by approved agencies and undergo biennial inspections.

Clinical laboratories also are subject to state regulation. CLIA provides that a state may adopt different or more stringent regulations than Federal law, and permits states to apply for exemption from CLIA if HHS determines that the state's laboratory laws are equivalent to, or more stringent than, CLIA. The State of New York's clinical laboratory regulations contain provisions that are more stringent than Federal law, and New York has received exemption from CLIA. Therefore, as long as New York maintains its CLIA-exempt status, laboratories in New York, including our laboratory, are regulated under New York law rather than CLIA. Our laboratory is licensed in New York and has continuing programs to ensure that its operations meet all applicable regulatory requirements.

The sanction for failure to comply with these regulations may be suspension, revocation, or limitation of a laboratory's CLIA certificate necessary to conduct business, significant fines and criminal penalties. The loss of, or adverse action against, a license, the imposition of a fine, or future changes in Federal, state and local laboratory laws and regulations (or in the interpretation of current laws and regulations) could have a material adverse effect on our business.

Clinical Laboratory Reimbursement

The health care industry has been undergoing significant change because third-party payors, such as Medicare (serving primarily patients 65 and older), Medicaid serving primarily indigent patients, health maintenance organizations and commercial insurers, have increased their efforts to control the cost, utilization and delivery of health care services. To address the problem of increasing health care costs, legislation has been proposed or enacted at both the Federal and state levels to regulate health care delivery in general and clinical laboratories in particular. Additional health care reform efforts are likely to be proposed in the future. In particular, we believe that reductions in reimbursement for Medicare services will continue to be implemented from time to time. Reductions in the reimbursement rates of other third-party payors, commercial insurer and health maintenance organizations are likely to occur as well. We cannot predict the effect that health care reform, if enacted, would have on our business, and there can be no assurance that such reforms, if enacted, would not have a material adverse effect on our business and operations.

Containment of health care costs, including reimbursement for clinical laboratory services, has been a focus of ongoing governmental activity. In 1984, Congress established the Medicare fee schedule for clinical laboratory services, which is applicable to patients covered under Part B of the Medicare program as well as patients receiving Medicaid. Clinical laboratories must bill Medicare directly for the services provided to Medicare beneficiaries and may only collect the amounts permitted under this fee schedule. Reimbursement to clinical laboratories under the Medicare Fee Schedule has been steadily declining since its inception. Furthermore, Medicare has mandated use of the Physicians Current Procedural Terminology ("CPT") for coding of laboratory services which has altered the way we bill these programs for some of our services, thereby reducing the reimbursement that we receive.

In March 1996, HCFA (now, the Center for Medicare and Medicaid Services or CMS) implemented changes in the policies used to administer Medicare payments to clinical laboratories for the most frequently performed automated blood chemistry profiles. Among other things, the changes established a consistent standard nationwide for the content of the automated chemistry profiles. Another change requires laboratories performing certain automated blood chemistry profiles to obtain and provide documentation of the medical necessity of tests included in the profiles for each Medicare beneficiary. Reimbursements have been reduced as a result of this change. Because a significant portion of our costs are fixed, these Medicare reimbursement reductions and changes have a direct adverse effect on our net earnings and cash flows. Future changes in Federal, state and local regulations (or in the interpretation of current regulations) affecting governmental reimbursement for clinical laboratory testing could result in material adverse effect on our business. In addition, reimbursement disapprovals by the third party payors, commercial insurers and health maintenance organizations, reductions or delays in the establishment of reimbursement rates, and carrier limitations on the insurance coverage of the Company's services or the use of the Company as a service provider could have a negative effect on the Company's future revenues.

interpretation of current regulations) affecting governmental reimbursement for clinical laboratory testing could have a material adverse effect on our business. We cannot predict, however, whether and what type of legislation will be enacted into law.

Anti Fraud and Abuse Laws

Existing Federal laws governing Medicare, as well as state laws, also regulate certain aspects of the relationship between healthcare providers, including clinical laboratories and their referral sources such as physicians, hospitals and other laboratories. One provision of these laws, known as the "Anti-Kickback Law," contains extremely broad proscriptions. Violation of this provision may result in criminal penalties, exclusion from Medicare, and significant civil monetary penalties. Under another Federal law, known as the "Stark" law or "self-referral prohibition," physicians who have an investment or compensation relationship with an entity furnishing clinical laboratory services (including anatomic pathology and clinical chemistry services) may not, subject to certain exceptions, refer clinical laboratory testing for Medicare patients to that entity. Similarly, laboratories may not bill Medicare or Medicaid or any other party for services furnished pursuant to a prohibited referral. Violation of these provisions may result in disallowance of Medicare for the affected testing services, as well as the imposition of civil monetary penalties. New York State also has laws similar to the Federal Stark and Anti-Kickback laws.

In recent years, the Federal Stark law, as well as New York State law, have also placed restrictions on the supplies and other items that laboratories may provide to their clients. These laws specify that laboratories may only provide clients with items or devices that are used solely to collect, transport or store specimens for the laboratory or to communicate results or tests. Items such as biopsy needles, snares and reusable needles are specifically prohibited from being supplied by laboratories to their clients. These laws represent a significant deviation from practices which previously occurred throughout the industry.

In February 1997, the OIG released a model compliance plan for laboratories. One key aspect of the model compliance plan is an emphasis on the responsibilities of laboratories to notify physicians that Medicare covers only medically necessary services. These requirements, and their likely effect on physician test ordering habits, focus on chemistry tests, especially routing tests, rather than on anatomic pathology services or the non-automated tests, which make up the majority of the Company's business measured in terms of net revenues. Nevertheless, they potentially could affect physicians test ordering habits more broadly. The Company is unable to predict whether, or to what extent, these developments may have an impact on the utilization of the Company's services.

The Company seeks to structure its arrangements with physicians and other customers to be in compliance with the anti-kickback, Stark and state laws, and to keep up-to-date on developments concerning their application by various means, including consultation with legal counsel. In addition, in order to address these various Federal and state laws, the Company has developed its own Corporate Compliance Program based upon the OIG' model program. The Company's Program focuses on establishing clear standards, training and monitoring of the Company's billing and coding practices. Furthermore, as part of this Program, the Company's Corporate Compliance Committee meets on a regular basis to review various operations and relationships as well as to adopt policies addressing these issues.

However, the Company is unable to predict how the laws described above will be applied in the future, and no assurances can be given that its arrangements or processes will not become subject to scrutiny under these laws.

Confidentiality of Health Information

The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") was signed into law on August 21, 1996, and it includes "administrative simplification" provisions designed to standardize common electronic transactions in health care and to protect the security and privacy of health information. Congress' purpose in promulgating HIPAA was to increase the efficiency of health care transactions while, at the same time, protecting the confidentiality of patient information. Final regulations have been adopted for electronic transaction and privacy standards. Further, final regulations adopting a national employer identifier to be used in electronic health care transactions have been finalized. In addition, there are proposed regulations regarding security standards and the assignment and use of unique provider identifiers in electronic health care transactions. These provisions have very broad applicability and they specifically apply to health care providers, which include physicians and clinical laboratories.

certain common health care transactions. With certain exceptions, these standards require that when we conduct certain transactions electronically with another provider, clearinghouse or health plan we must comply with the standards set forth in the regulations. The regulations establish standard data content and formats for submitting electronic claims and other administrative health transactions. All health care providers will be able to use the electronic format to bill for their services and all health plans and providers will be required to accept standard electronic claims, referrals, authorizations, and other transactions. We are required to comply with these standards by October 15, 2003 as we requested a one year extension to the compliance date. Despite the initial costs, the use of uniform standards for all electronic transactions could lead to greater efficiency in processing claims and in handling health care information.

The Privacy regulations, which were modified in August 2002, create specific requirements for the use and disclosure of protected health information ("PHI"). Providers will be required to develop numerous policies and procedures in order to meet these requirements. Furthermore, we will need to establish mechanisms to safeguard the PHI, which is used or maintained in any format (e.g., oral, written, or electronic). For purposes of the criminal and civil penalties imposed under Title XI of the Social Security Act, the compliance date for the privacy regulation is April 2003.

Complying with both the Electronic Transaction and Privacy rules will require significant effort and expense for virtually all entities that conduct health care transactions electronically and handle patient health information. Furthermore, when the Security Regulations are finalized, the company may need to expend additional funds to make efforts to comply with those standards. At this time, the Company is unable to estimate the total cost or impact of the regulations.

Infectious Wastes and Radioactive Materials

We are subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as to the safety and health of laboratory employees. All our laboratories are required to operate in accordance with applicable federal and state laws and regulations relating to biohazard disposal of all facilities specimens and we use outside vendors to dispose such specimens. Although we believe that we comply in all material respects with such federal, state and local laws, our failure to comply with those laws could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions.

Occupational Safety

In addition to its comprehensive regulation of safety in the workplace, the Federal Occupational Safety and Health Administration ("OSHA") has established extensive requirements relating to workplace safety for health care employers, including clinical laboratories, whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis B virus. These regulations, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to, and transmission of, blood-borne pathogens. The use of controlled substances in testing for drugs of abuse is regulated by the Federal Drug Enforcement Administration. We are also subject to OSHA's requirement that employers using hazardous chemicals communicate the properties and hazards presented by those chemicals to their employees. We believe that we are in material compliance with these OSHA requirements. Our failure to comply with those regulations and requirements could subject us to tort liability, civil fines, criminal penalties and/or other enforcement actions.

Other Regulation

Our business is and will continue to be subject to regulation under various state and federal environmental, safety and health laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, and the Atomic Energy Act or their state law analogs. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in our operations and wastes generated by our operations. We are required to possess licenses under, or are otherwise subject to federal and state regulations pertaining to, the handling and disposal of medical specimens, infectious and hazardous waste and radioactive materials.

We believe that we are in material compliance with applicable environmental, safety and health laws and that our continual compliance therewith will not have a material adverse effect on our business. All of our laboratories are operated in accordance with applicable federal and state laws and regulations relating to hazardous substances and wastes, and we use qualified third-party vendors to dispose of biological specimens and other hazardous wastes. Although we believe that we comply in all material respects with such federal, state and local laws, our failure to comply with those laws could subject us to denial of the right to conduct business, civil fines, criminal penalties and/or other enforcement actions. Environmental contamination resulting from spills or disposal of hazardous substances generated by our

operations, even if caused by a third-party contractor or occurring at a remote location could result in material liability.

Manufacturing and Facilities

We manufacture the majority of our products internally. Most of our production and clinical laboratory operations take place at our 43,000 square feet facilities in Farmingdale, New York. We have a completely integrated manufacturing facility, with special handling facilities and clean rooms.

We also contract with qualified third-party contractors to manufacture our products in cases where we deem it appropriate, for example, when it is not cost-effective to produce a product ourselves or where we seek to leverage the expertise of another manufacturer in a certain area.

Employees

As of July 31, 2002, we employed 205 full-time and 26 part-time employees. Of the full-time employees, 49 were engaged in research, development, manufacturing, administrative support and marketing of research products and 156 at the clinical reference laboratories. Our scientific staff possesses a wide range of experience and expertise in the areas of recombinant DNA, nucleic acid chemistry, molecular biology and immunology. We believe that the relationships we have established with our employees are good.

Information Systems

We believe that with respect to our clinical reference laboratory business, the health care provider's need for data will continue to place high demands on our information systems staff. We believe that the efficient handling of information involving clients, patients, payors and other parties will be a critical factor in our future success.

Quality Assurance

We consider the quality of our clinical reference laboratory tests to be of critical importance, and, therefore, we established a comprehensive quality assurance program designed to help assure accurate and timely test results. In addition to the compulsory external inspections and proficiency programs demanded by the Medicare program and other regulatory agencies, our clinical laboratory has in place systems to emphasize and monitor quality assurance.

In addition to our own internal quality control programs, our laboratory participates in numerous externally administered, blind quality surveillance programs, including on-site evaluation by the College of American Pathologists ("CAP") proficiency testing program and the New York State survey program. The blind programs supplement all other quality assurance procedures and give our management the opportunity to review our technical and service performance from the client's perspective.

The CAP accreditation program involves both on-site inspections of our laboratory and participation in the CAP's proficiency testing program for all categories in which our laboratory is accredited by the CAP. The CAP is an independent nongovernmental organization of board certified pathologists, which offers an accreditation program to which laboratories can voluntarily subscribe. A laboratory's receipt of accreditation by the CAP satisfies the Medicare requirement for participation in proficiency testing programs administered by an external source. Our clinical laboratory facilities are accredited by the CAP.

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements to encourage companies to provide prospective information about their companies without fear of litigation so long as those statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in the statement. The Company desires to take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and is including this section herein in order to do so. Accordingly, the Company hereby identifies the following important factors that could cause the Company's actual financial results to differ materially from those projected, forecast, estimated, or budgeted by the Company in forward-looking statements.

- (a) Heightened competition, including the intensification of price competition.
- (b) Impact of changes in payor mix, including the shift from

traditional, fee-for-service medicine to managed-cost health care.

- (c) Adverse actions by governmental or other third-party payors, including unilateral reduction of fee schedules payable to the Company.

- (d) The impact upon the Company's collection rates or general or administrative expenses resulting from compliance with Medicare administrative policies including specifically the HCFA's recent requirement that laboratories performing certain automated blood chemistry profiles obtain and provide documentation of the medical necessity of tests included in the profiles for each Medicare beneficiary.
- (e) Failure to obtain new customers, retain existing customers or reduction in tests ordered or specimens submitted by existing customers.
- (f) Adverse results in significant litigation matters.
- (g) Denial of certification or licensure of any of the Company's clinical laboratories under CLIA, by Medicare programs or other Federal, state or local agencies.
- (h) Adverse publicity and news coverage about the Company or the clinical laboratory industry.
- (i) Inability to carry out marketing and sales plans.
- (j) Loss or retirement of key executives.
- (k) Impact of potential patent infringement by others or the Company.
- (l) Inability to obtain patent protection or secure and maintain proprietary positions on its technology.
- (m) Dependence on new technologies for our product development and dependence on product candidates in early stages of development.
- (n) Clinical trials for our products will be expensive and their outcome is uncertain. We incur substantial expenses that might not result in viable products.
- (o) May need additional capabilities in the future, if additional capital is not available, we may need to curtail or cease operations.

Item 2. Properties

The following are the principal facilities of the Company:

<TABLE>
<CAPTION>

Location	Principal Operations	Approximate Floor Area (sq. ft.)	Approximate Annual Base Rent	Expiration Date
60 Executive Blvd. Farmingdale, N.Y. 2004	Corporate headquarters, clinical reference and development facilities (See note 5 of Notes to Consolidated Financial Statements)	43,000	\$1,140,000	November 30,
527 Madison Ave. 2003 New York, NY	Executive office	6,400	\$ 288,000	December,

</TABLE>

Management believes that the current facilities will be adequate for current operating needs and in the foreseeable future.

Item 3. Legal Proceedings

In June 1999, the Company filed suit in the United States District Court for the Southern District of New York against Gen-Probe Incorporated, Chugai Pharma U.S.A., Inc., Chugai Pharmaceutical Co., Ltd., bioMerieux, Inc., bioMerieux SA, and Becton Dickinson and Company, charging them with infringing the Company's U.S. Patent 4,900,659, which concerns probes for the detection of the bacteria that causes gonorrhea. On January 26, 2001, the court granted the defendants' motion for summary judgment that the Company's patent is invalid. On July 15, 2002, the Court of Appeals for the Federal Circuit reversed the judgment of invalidity and remanded the case to the district court for further proceedings. The proceedings on remand are at an early stage. There can be no assurance that the Company will be successful in these proceedings. However, even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact.

On March 6, 2002, the Company was named, along with certain of its officers and directors among others, in a complaint entitled Lawrence F. Glaser and Maureen Glaser, individually and on behalf of Kimberly, Erin, Hannah, and Benjamin Glaser v. Hyman Gross, Barry Weiner, Enzo Biochemical Inc., Elazar Rabbani, Shahram Rabbani, John Delucca, Dena Engelhardt, Richard Keating, Doug Yeats, and Docs I-50, in the U.S. District Court for the Eastern District of Virginia. The complaint was filed by an investor in the Company who has filed for bankruptcy protection and his family. The complaint alleges securities and common law fraud and breach of fiduciary duty and seeks in excess of \$150 million in damages. On August 22, 2002, the complaint was voluntarily dismissed, however a new substantially similar complaint was filed at the same time. On October 21, 2002, the Company and the other defendants filed a motion to dismiss the complaint, this motion is pending before the Court.

In March 2002, Enzo Life Sciences, a subsidiary of the Company, filed suit in the United States District Court for the District of Delaware against Digene Corp., charging it with infringing the Company's U.S. Patent No. 6,221,581 B1, which concerns a novel process for detecting nucleic acids of interest. On May 31, 2002, Digene filed counterclaims in that suit against Enzo Life Sciences and the Company, including business tort counterclaims relating to the '581 patent. The case is at an early stage. There can be no assurance that the Company and Enzo Life Sciences will be successful in these proceedings. However, even if Enzo Life Sciences is not successful in its patent infringement suit, management does not believe that there will be a significant adverse monetary impact. With respect to Digene's counterclaims, the Company and Enzo Life Sciences believe them to be without merit and intend to defend themselves vigorously.

In October 2002, the Company filed suit in the United States District Court of the Southern District of New York against Amersham plc, Amersham Biosciences, Perkin Elmer, Inc., Perkin Elmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc. and Orchid Biosciences, Inc. The counts set forth in the suit are for breach of contract; patent infringement; unfair competition under state law; unfair competition under federal law; tortious interference with business relations; and fraud in the inducement of contract. The complaint alleges that these counts arise out of the defendants' breach of distributorship agreements with the Company concerning labeled nucleotide products and technology, and the defendants' infringement of patents covering the same. There can be no assurance that the Company will be successful in this litigation. However, even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were brought to a vote of the Company's stockholders in the fourth fiscal quarter ended July 31, 2002.

PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters

The common stock of the Company is traded on the New York Stock Exchange (Symbol:ENZ). The following table sets forth the high and low price of the Company's Common Stock for the periods indicated as reported on the New York Stock Exchange.

	High	Low
2001 Fiscal Year (August 1, 2000 to July 31, 2001):		
1st Quarter	\$ 58.81	\$34.29

2nd Quarter	\$ 42.06	\$17.96
3rd Quarter	\$ 23.18	\$13.95
4th Quarter	\$ 34.98	\$22.87

2002 Fiscal Year (August 1, 2001 to July 31, 2002):

1st Quarter	\$ 28.88	\$13.58
2nd Quarter	\$ 26.13	\$19.02
3rd Quarter	\$ 21.99	\$17.30
4th Quarter	\$ 19.45	\$11.09

On October 8, 2002, the last sale price of the Common Stock of the Company as reported on the New York Stock Exchange was \$14.88.

As of October 8, 2002, the Company had approximately 1,233 record holders of its Common Stock.

The Company has not paid a cash dividend on its Common Stock and intends to continue to follow a policy of retaining future earnings to finance its operations. Accordingly, the Company does not anticipate the payment of cash dividends to holders of Common Stock in the foreseeable future.

The Company declared a 5% stock dividend on January 23, 2002 payable February 27, 2002 to shareholders of record as of February 2, 2002. The Company declared a 5% stock dividend on January 16, 2001 payable March 20, 2001 to shareholders of record as of February 27, 2001. The shares and per share data have been adjusted to retroactively reflect these stock dividends. The Company recorded a charge to accumulated deficit and a credit to common stock and additional paid-in capital in the amount of approximately \$26,988,000 in fiscal 2002, and \$32,274,000 in fiscal 2001, which reflects the fair value of the dividends on the date of declaration.

Equity Compensation Plan Disclosure

The following table summarizes equity compensation plans approved by security holders and equity compensation plans that were not approved by security holders as of July 31, 2002:

Securities Available for Under Equity (Excluding Plan category Column (a))	(a)	(b)	(c)
	Number of Securities To be Issued Upon Exercise of Outstanding Options, Warrants and Rights	Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights	Number of Remaining Future Issuance Compensation Plans Securities Reflected in
<S>	<C>	<C>	<C>
Equity compensation plans (stock options) approved by security holders 1,205,426	2,577,234	\$10.34	
Equity compensation plans not Approved by security holders	---	---	---
Total 1,205,426	2,577,234	\$10.34	

Item 6. Selected Financial Data

The selected operating results for the years ended July 31, 2002, 2001 and 2000 and the Financial Position data as of July 31, 2002 and 2001, have been derived from the Company's audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The selected operating results for the years ended July 31, 1999 and 1998, and the selected financial position data as of July 31, 2000, 1999 and 1998 are derived from the Company's audited consolidated financial statements which are not included in the Annual Report on

The following tables summarize the Company's consolidated statement of operations and balance sheet data. This information should be read together with the discussion in "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the Company's consolidated financial statements and notes to those statements included elsewhere in the Annual Report on Form 10-K.

<TABLE>
<CAPTION>

	For the Years Ended July 31,				
	2002	2001	2000	1999	1998
	(In thousands, except per share data)				
Operating Results:					
<S>	<C>	<C>	<C>	<C>	<C>
Operating revenues	\$ 54,015	\$ 52,266	\$ 42,847	\$ 36,966	\$ 33,702
Interest income	1,350	3,003	2,585	1,984	1,885
Income before (provision) benefit for taxes on income	10,340	12,231	7,668	5,387	2,570
(Provision) benefit for taxes on income	(3,417)	(5,418)	(1,044)	1,128	822
Net income	\$ 6,923	\$ 6,813	\$ 6,625	\$ 6,515	\$ 3,392
Basic net income per common share:	\$ 0.24	\$ 0.24	\$ 0.24	\$ 0.24	\$ 0.12
Diluted net income per common share:	\$ 0.24	\$ 0.23	\$ 0.22	\$ 0.23	\$ 0.12
Denominator for per share calculation:					
Basic	28,444	28,349	27,927	27,489	27,180
Diluted	29,322	29,532	29,752	28,089	28,385
Financial Position:					
Working capital	\$ 92,967	\$ 85,094	\$ 74,094	\$ 59,323	\$ 52,973
Total assets	\$ 109,291	\$ 102,931	\$ 92,886	\$ 78,901	\$ 72,153
Stockholders' equity	\$ 104,733	\$ 97,517	\$ 87,176	\$ 75,648	\$ 68,783

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. See "Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995". Because of the foregoing factors, you should not rely on past financial results as an indication of future performance. We believe that period-to-period comparisons of our financial results to date are not necessarily meaningful and expect that our results of operations might fluctuate from period to period in the future.

Liquidity and Capital Resources

At July 31, 2002, our cash and cash equivalents totaled \$67.1 million, an increase of \$8.5 million from July 31, 2001. We had working capital of \$93.0 million at July 31, 2002 compared to \$85.1 million at July 31, 2001.

Net cash provided by operating activities for the year ended July 31, 2002 was approximately \$9.6 million as compared to net cash provided by operating activities of \$8.0 million for the year ended July 31, 2001. The increase in net cash provided by operating activities from fiscal 2001 to fiscal 2002 was due to the net change in operating assets and liabilities compared to the prior year primarily inventory, accounts receivable and prepaid taxes.

Net cash used in investing activities decreased approximately \$.5

million from fiscal 2001, primarily as a result of an decrease in capital expenditures and patent costs deferred.

Net cash provided by financing activities decreased by \$1.2 million from fiscal 2001 primarily as a result of the decrease in proceeds from the exercise of stock options.

Net accounts receivable of \$20.3 million and \$24.6 million represented 137 days and 172 days of operating revenues at July 31, 2002 and 2001, respectively. The change in net accounts receivable is due to a decrease in accounts receivable at the clinical reference laboratory of approximately \$6.3 million and an increase of research products accounts receivable of approximately \$2.0 million. The decrease is primarily due to the decrease in revenue from the clinical laboratory and the effect of the health maintenance organization contract that were cancelled in fiscal 2002.

The Company has entered into various real estate operating leases with both related and unrelated parties. See Note 5 to the Consolidated Financial Statements for a further description of these various leases.

The total future payments under these contractual obligations as of July 31, 2002 is as follows:

<TABLE>
<CAPTION>

	Payments Due by Period			
	Total	Less than 1 year	1-3 years	4-5 years
	-----	-----	-----	-----
<S>	<C>	<C>	<C>	<C>
Operating Leases	\$3,097,000	\$1,504,000	\$1,576,000	\$17,000
	-----	-----	-----	-----
Total Contractual Cash Obligations	\$3,097,000	\$1,504,000	\$1,576,000	\$17,000
	=====	=====	=====	=====

</TABLE>

We believe that our current cash position is sufficient for our foreseeable liquidity and capital resource needs, although there can be no assurance those future events will not alter such view.

Management is not aware of any material claims, disputes or settled matters concerning third-party reimbursements that would have a material effect on our financial statements.

Critical Accounting Policies

General

The Company's discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc. consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses; these estimates and judgments also affect related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to contractual allowance, allowance for uncollectible accounts, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that of our significant accounting policies (see Note 1 the of consolidated financial statements), the following may involve a higher degree of judgment and complexity than other accounting policies:

Revenue Recognition

Revenues from services from the clinical reference laboratory are recognized when services are provided. The Company's revenue is based on amounts billed or billable for services rendered, net of contractual adjustments and other arrangements made with third-party payors to provide services at less than established billing rates. Revenues from research product sales are recognized when the products are shipped.

Contractual Allowances

The percentage of the Company's revenues derived from Medicare, third party payers, commercial insurers and managed care patients continue to increase. The Medicare regulations and various managed care contracts are often complex and may include multiple reimbursement mechanisms for different types of services provided in our clinical laboratory. We estimate the allowance for contractual allowances on a payer-specific basis given our interpretation of the applicable regulations and historical calculations. However, the services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from our estimates. Additionally, updated regulations occur frequently necessitating continual review and assessment of the estimation process by management.

Allowance for Doubtful Accounts

The Company's ability to collect outstanding receivables from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for which primary insurance has paid but a patient portion remains outstanding. The Company estimates the allowance for doubtful accounts primarily based upon the age of the accounts since invoice date. The Company continually monitors its accounts receivable balances and utilizes cash collections data to support the basis for its estimates of the provision for doubtful accounts. Significant changes in payer mix or regulations could have a significant impact on the Company's results of operations and cash flows.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is more likely than not the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Impairment of Long-Lived Assets

The Company evaluates the requirement to recognize impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. Company management believes that no impairment to its long-lived assets has occurred.

Results of Operations

Fiscal 2002 Compared to Fiscal 2001

Revenues from operations for the fiscal year ended July 31, 2002 were \$54.0 million an increase of \$1.8 million over revenues from operations for the fiscal year ended July 31, 2001. This increase was due to an increase of \$8.9 million in revenues from our research product sales operations offset by a decrease of \$7.1 million in revenues from clinical reference laboratory operation over revenues for such activities in fiscal 2001. The decline of clinical laboratory services revenue was due primarily to reduced reimbursement rates which have been experienced from various managed care agreements and the negative results of an unprofitable contract which was cancelled in fiscal 2002. Clinical laboratory services are provided to patients covered by various third party payor programs, including Medicare and health maintenance organizations ("HMO's"). Billings for services are included in revenue net of allowances for contractual discounts and allowances paid for differences between the amounts billed and the estimated amount to be paid. Recent trends had indicated a decrease in the collection rates from the Medicare Program, certain third party payors and HMO's. The effect of such reduced collection rates have been reflected in fiscal 2002. The increase in research product sales resulted primarily from an increase in direct sales of research products of labeling and detection reagents for the genomics and sequencing markets. The Company has certain non-exclusive distribution agreements, which provide for consideration to be paid to the distributors for the manufacture of certain products. Such consideration was previously included in cost of research product revenues. In accordance with recently issued accounting pronouncements, the Company has reclassified consideration provided to distributors under these non-exclusive distribution agreements as a reduction to research product revenues. The prior years comparative amounts have been reclassified to be consistent with the current year presentation. This change reflects a new reporting presentation only and did not affect the Company's gross profit or net income as previously reported.

The cost of clinical laboratory services decreased by \$.4 million primarily due to a decrease in direct operating expenses based on decreased volume of testing in fiscal 2002. The cost of sales for research products decreased as a result of improved efficiency in the manufacturing of the direct sales of research products.

Research and development expenses increased by approximately \$.1 million as a result of an increase in the clinical trial studies.

Selling expenses increased by approximately \$.5 million primarily due to an increase in costs associated with the increase in revenue. General and Administrative expenses decreased by .3 million due to a decrease in personnel costs.

Our provision for uncollectible accounts receivable increased by \$2.2 million, primarily due to the recent trends that indicated a decrease in the collection rates from the certain third party payors and HMO's. The effect of such reduced collection rates have been reflected in fiscal 2002.

Interest income, decreased by \$1.7 million as a result of a decrease in interest rates in fiscal 2002 as compared to fiscal 2001.

In fiscal 2002 and 2001, we recorded a provision for income taxes of \$3.4 and \$5.4 million, respectively, which was based on the combined effective federal, state and local income tax rates. In fiscal 2002, we realized the benefit of certain tax credits and certain extraterritorial income is excludable from taxes that resulted in a lower effective tax rate in fiscal 2002 as compared to fiscal 2001.

Net accounts receivable from our clinical laboratory operations of \$13.8 million and \$20.1 million represented an average of 180 days and 208 days of operating revenues at July 31, 2002 and 2001, respectively.

Income before provision for taxes on income from research and development activities and related costs was \$16.6 million in fiscal 2002, as compared to income before provision for taxes on income of \$8.3 million in fiscal 2001. The increase in the profit resulted primarily from an increase in direct sales of research products of labeling and detection reagents for the genomics and sequencing markets. Income (loss) before provision for taxes on income from the clinical reference laboratories activities amounted to a \$3.8 million loss for fiscal 2002, as compared to \$3.8 million of income for fiscal 2001. The loss is primarily due to the recent trends that indicated a decrease in the collection rates from the Medicare Program, certain third party payors and HMO's.

Fiscal 2001 Compared to Fiscal 2000

Revenues from operations for the fiscal year ended July 31, 2001 were \$52.3 million an increase of \$9.4 million over revenues from operations for the fiscal year ended July 31, 2000. This increase was due to an increase of \$3.7 million in revenues from our clinical reference laboratory operations and an increase of \$5.7 million in revenues from research product sales over revenues for such activities in fiscal 2000. The increase in revenues from the clinical laboratory operations resulted primarily from an increase in volume of esoteric testing and from an increase in doctor accounts being serviced. The increase in research product sales resulted primarily from and an increase in direct sales of research products of labeling and detection reagents for the genomics and sequencing markets.

The cost of clinical laboratory services increased by \$2.0 million primarily due to an increase in direct operating expenses based on the increased sales volume of testing in fiscal 2001. In addition, the cost of sales for research products decreased as a result of a change in the revenue mix.

Research and development expenses increased by approximately \$.6 million as a result of an increase in the clinical trial studies and the expansion of certain research activities.

Selling expenses increased by approximately \$.6 million primarily due to an increase in costs associated with the increase in revenue. General and Administrative expenses increased by approximately \$.9 million as a result of an increase in facility overhead costs associated with the increase in testing volume at the clinical laboratory facilities.

Our provision for uncollectible accounts receivable increased by \$.7 million, primarily due to increased revenues from our clinical reference laboratory.

Interest income, increased by \$.4 million as a result of an increase in

In fiscal 2001, we recorded a provision for income taxes of \$5.4 million, which was based on the combined effective federal, state and local income tax rates. In fiscal 2000 we recorded a provision for income taxes of \$1.0 million which included a deferred benefit from the change in the deferred tax asset valuation reserve and benefits recognized from net operating losses.

Net accounts receivable from our clinical laboratory operations of \$20.1 million and \$16.6 million represented an average of 190 and 193 days of operating revenues at July 31, 2001 and 2000, respectively.

Income before (provision) benefit for taxes on income from research and development activities and related costs was \$8.3 million in fiscal 2001, as compared to income before (provision) benefit for taxes on income of \$3.8 million in fiscal 2000. The increase in the profit is principally related to the increase in sales of research products. Income before (provision) benefit for taxes on income from the clinical reference laboratories activities amounted to \$3.8 million for fiscal 2001, as compared to \$3.7 million for fiscal 2000.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable

Item 8. Financial Statements and Supplementary Data

The response to this item is submitted in a separate section of this report. See Item 15(a) (1) and (2)

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

PART III

Item 10. Directors and Executive Officers of the Registrant

(a) Directors - The following sets forth certain information regarding directors of the Company who are not executive officers of the Company. Information with respect to directors of the Company who are also executive officers of the Company appears below under the subcaption "Executive Officers." The Company has a classified Board of Directors consisting of three classes.

JOHN B. SIAS (age 75) has been a Director of the Company since January 1982. Mr. Sias had been President and Chief Executive Officer of Chronicle Publishing Company since April 1993 to January 2000. From January 1986 until April 1993, Mr. Sias was President of ABC Network Division, Capital Cities/ABC, Inc. From 1977 until January 1986 he was the Executive Vice President, President of the Publishing Division (which includes Fairchild Publications) of Capital Cities Communications, Inc.

JOHN J. DELUCCA (age 59) has been a Director of the Company since January 1982. Mr. Delucca had been Chief Financial Officer & Executive Vice President, Finance & Administration of Coty, Inc. from January 1999 to January 2002. From October 1993 until January 1999, he was Senior Vice President and Treasurer of RJR Nabisco, Inc. From January 1992 until October 1993, he was managing director and Chief Financial Officer of Hascoe Associates, Inc. From October 1, 1990 to January 1992 he was President of The Lexington Group. From September 1989 until September 1990, he was Senior Vice President-Finance of the Trump Group. From May 1986 until August 1989, he was senior Vice President-Finance at International Controls Corp. From February 1985 until May 1986, he was a Vice President and Treasurer of Textron, Inc. Prior to that he was a Vice President and Treasurer of the Avco Corporation, which was acquired by Textron.

IRWIN C. GERSON (age 72) has been a Director of the Company since May 8, 2001. From 1995 until December 1998, Mr. Gerson served as Chairman of Lowe McAdams Healthcare and prior thereto had been, since 1986, Chairman and Chief Executive Officer of William Douglas McAdams, Inc., one of the largest advertising agencies in the U.S. specializing in pharmaceutical marketing and communications to healthcare professionals. In February 2000, he was inducted into the Medical Advertising Hall of Fame. Mr. Gerson has a B.S. in Pharmacy from Fordham University and an MBA from the NYU Graduate School of Business Administration. He is a director of Andrx Corporation, which specializes in proprietary drug delivery technologies, and eXegenice Pharmaceuticals, Inc., a biopharmaceutical drug development company, both Nasdaq listed public companies.

STANFORD S. WARSHAWSKY (age 64) has been a Director of the Company since August 1, 2002. Mr. Warshawsky has been Co-President of Arnhold and S.

Bleichroeder Holdings since 1994, having joined the firm in 1972. He previously was with the law firm of Shearman & Sterling. Mr. Warshawsky is Co-President of Arnhold and S. Bleichroeder Advisers, Inc., a money management advisory group, in addition to being Chairman of the firm's First Eagle Funds, First Eagle SoGen Funds and First Eagle SoGen Variable Funds, Inc. Mr. Warshawsky is a member of the New York Stock Exchange's Nominating Committee, of which he also was a former Chairman, a member of the Big Board's New York Area Firms Advisory Committee, a Director of the German-American Chamber of Commerce and a Fellow in the Foreign Policy Association. He is also a member of the Bar Associations of both New York State and Virginia State. Mr. Warshawsky holds a Bachelor of Business Administration degree from the University of Michigan and a JD from the University of Virginia School of Law.

26

MELVIN F. LAZAR, CPA (age 63) has been a Director of the Company since August 1, 2002. Mr. Lazar was a founding partner of the public accounting firm of Lazar, Levine & Felix (LLP) since 1969 until October, 2002. He is an expert on the topic of business valuations and merger and acquisition activities. Lazar, Levine & Felix is the 17th largest auditor of publicly held companies in the U.S. Mr. Lazar is a board member and serves as the Chairman of the Audit Committee of privately owned Active Media Services, Inc., the largest corporate barter company in the nation. Mr. Lazar holds a Bachelor of Business Administration degree from The City College of New York.

During the fiscal year ended July 31, 2002, there were five (5) formal meetings of the Board of Directors, several actions by unanimous consent and several informal meetings. During the fiscal year ended July 31, 2002, the Board of Directors had an Audit Committee and Stock Option Committee. The Audit Committee had five (5) formal meetings and the Stock Option Committee had (1) one formal meeting in fiscal 2002.

The Audit Committee is authorized to review proposals of the Company's auditors regarding annual audits, recommend the engagement or discharge of the auditors, review recommendations of such auditors concerning accounting principles and the adequacy of internal controls and accounting procedures and practices, to review the scope of the annual audit, to approve or disapprove each professional service or type of service other than standard auditing services to be provided by the auditors, and to review and discuss the audited financial statements with the auditors. The current members consist of Messrs. Sias, Delucca and Lazar.

The Stock Option Committee had the plenary authority in its discretion to determine the purchase price of the Common Stock issuable upon the exercise of each option, to determine the employees to whom, and the time or times at which, options shall be granted and the number of shares to be issuable upon the exercise of each option, to interpret the plans, to prescribe, amend and rescind rules and regulations relating to them, to determine the term and provisions of the respective option agreements and to make all other determinations deemed necessary or advisable for the administration of the plans. The current members consist of Messrs, Sias and Delucca.

In October, 2002, the Board of Directors established a Compensation Committee. The Compensation Committee has the power and authority to (i) establish a general compensation policy for the officers and employees of the Corporation, including to establish and at least annually review officers' salaries and levels of officers' participation in the benefit plans of the Corporation, (ii) prepare any reports that may be required by the regulations of the Securities and Exchange Commission or otherwise relating to officer compensation, (iii) approve any increases in directors' fees, and (iv) exercise all other powers of the Board of Directors with respect to matters involving the compensation of employees and the employee benefits of the Corporation as shall be delegated by the Board of Directors to the Compensation Committee. The current members of the Compensation Committee are Messrs, Gerson, Warshawsky and Delucca.

In October, 2002, the Board of Directors also established a Nominating Committee. The Nominating Committee has the power to recommend to the Board of Directors prior to each annual meeting of the shareholders of the Corporation: (i) the appropriate size and composition of the Board of Directors; and (ii) nominees: (1) for election to the Board of Directors for whom the Corporation should solicit proxies; (2) to serve as proxies in the connection with the annual shareholders' meeting; and (3) for election to all committees of the Board of Directors other than the Nominating Committee. The current members of the Nominating Committee are Messrs, Gerson, Warshawsky and Sias.

27

(b) Executive Officers - The following table sets forth the names and

positions of all of the current executive officers of the Company:

<TABLE>
<CAPTION>

Name ----	Position -----
<S>	<C>
Elazar Rabbani, Ph.D.	Chief Executive Officer, Chairman of the Board of Directors
Shahram K. Rabbani	Chief Operating Officer, Secretary, Treasurer
Barry W. Weiner	President
Dean Engelhardt, Ph.D.	Executive Vice President
Norman E. Kelker, Ph.D.	Senior Vice President
Herbert B. Bass	Vice President of Finance
Barbara E. Thalenfeld, Ph.D.	Vice President, Corporate Development
David C. Goldberg	Vice President, Business Development

DR. ELAZAR RABBANI (age 58) has served as the Company's Chairman of the Board of Directors and Chief Executive Officer since its inception in 1976. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. degree in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.

SHAHRAM K. RABBANI (age 50) has served as Chief Operating Officer, Secretary, and Treasurer of the Company since November 1996, as Executive Vice President from September 1981 to November 1996 and as Vice President, Treasurer and a Director of the Company since its inception. He is also the President of Enzo Clinical Labs, Inc. Mr. Rabbani received a Bachelor of Arts degree in Chemistry from Adelphi University located in Long Island, NY.

BARRY W. WEINER (age 52) has served as President of the Company since November 1996 and as a Director of the Company since its inception. Mr. Weiner has served as an Executive Vice President of the Company from September 1981 to November 1996, as a Vice President of the Company from the Company's organization to November 1996 and as Secretary of the Company from March 1980 to November 1996. He was employed by Colgate-Palmolive Company from August 1974 to March 1980, where he held several managerial and marketing positions. Mr. Weiner received his Bachelor of Science degree in Economics from New York University and M.B.A. from Boston University. Mr. Weiner is a Director of the New York State Biotechnology Association.

DR. DEAN ENGELHARDT (age 62) has served as Executive Vice President since July 2000, as Senior Vice President since January 1989, and as Vice President since September 1981. Prior to joining the Company, he was Associate Professor of Microbiology at Columbia University College of Physicians and Surgeons. He obtained his Ph.D. in Molecular Genetics from Rockefeller University.

DR. NORMAN E. KELKER (age 63) has been a Senior Vice President of the Company since January 1989. In September 1981, Dr. Kelker joined the Company as Vice President of Scientific Affairs. Prior to being employed by the Company, he was an Associate Professor in the Department of Microbiology of the New York University School of Medicine since 1975. He holds a Ph.D. in Microbiology and Public Health from Michigan State University.

HERBERT B. BASS (age 54) is Vice President of Finance of the Company since 1989. From 1986 to 1989, Mr. Bass was the Corporate Controller of Enzo. Before joining the Company in 1986, Mr. Bass held various positions at Danziger & Friedman, Certified Public Accountants, from 1979 to 1986, the most recent of which was audit manager. For the preceding seven years he held various positions at Berenson & Berenson, C.P.A.'s located in New York City. Mr. Bass holds a Bachelor of Business Administration degree in accounting from Barnard M. Baruch College in New York City.

DR. BARBARA E. THALENFELD (age 62) is Vice President of Corporate Development and Vice President of Clinical Affairs for Enzo Therapeutics and has been employed with Enzo since 1982. Prior to joining the Company she held an NIH research fellowship at Columbia University. She received a Ph.D. at the Institute of Microbiology at Hebrew University in Jerusalem and a Masters of Science degree in Biochemistry from Yale University. Dr. Thalenfeld also completed a Post Doctoral Fellowship in the Department of Biological Science at Columbia University.

DAVID C. GOLDBERG (age 45) is Vice President of Business Development. Prior to joining Enzo in 1985, he was employed at DuPont NEN Products where he held several managerial and marketing positions. He received a Masters of Science degree in Microbiology from Rutgers University and a Masters of Business Administration in Finance from New York University.

Dr. Elazar Rabbani and Shahram K. Rabbani are brothers and Barry W. Weiner is their brother-in-law.

Item 11. Executive Compensation

The information required under this item will be set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2002 and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management

The information required under this item will be set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2002 and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions

The information required under this item will be set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2002 and is incorporated herein by reference.

Item 14. Controls and Procedures

There have been no significant changes in the Company's internal controls or other factors that could significantly affect those controls since the date of the Company's last evaluation of its internal controls, and there have been no corrective actions with regard to significant deficiencies and material weaknesses in such controls.

PART IV

Item 15. Exhibits, Financial Statement Schedules, and Reports on Form 8-K

(a) (1) Consolidated Financial Statements

Consolidated Balance Sheets - July 31, 2002 and 2001
Consolidated Statements of Operations-
Years ended July 31, 2002, 2001 and 2000
Consolidated Statements of Stockholders' Equity-
Years ended July 31, 2002, 2001 and 2000
Consolidated Statements of Cash Flows-
Years ended July 31, 2002, 2001 and 2000
Notes to Consolidated Financial Statements.

(2) Financial Statement Schedule
Schedule II - Valuation and Qualifying Accounts

All other schedules have been omitted because the required information is included in the consolidated financial statements or the notes thereto or because they are not required.

(3) Exhibits

The following documents are filed as Exhibits to this Annual Report on Form 10-K:

Exhibit No -----	Description -----
3(a)	Certificate of Incorporation, as amended March 17, 1980. (1)
3(b)	June 16, 1981 Certificate of Amendment of the Certificate of Incorporation. (2)
3(c)	Certificate of Amendment to the Certificate of Incorporation. (11)
3(d)	Bylaws. (1)
10(a)	1983 Incentive Stock Option Plan. (4)

10(b)	1993 Incentive Stock Option Plan. (5)
10(c)	Employment Agreement with Elazar Rabbani. (5)
10(d)	Employment Agreement with Shahram Rabbani. (5)

- 10(e) Employment Agreement with Barry Weiner. (5)
- 10(f) 1994 Stock Option Plan (6).
- 10(g) Agreement with Corange International Limited (Boehringer Mannheim) effective April 1994. (19) (7)
- 10(h) Agreement with Amersham International effective February 1995. (7)
- 10(i) Agreement with Dako A/S effective May 1995. (7)
- 10(j) Agreement with Baxter Healthcare Corporation (VWR Scientific Products) effective September 1995. (7)
- 10(k) Agreement with Yale University and amendments thereto. (7)
- 10(l) Agreement with The Research Foundation of the State of New York effective May 1987. (7)
- 10(m) 1999 Stock Option Plan filed. (8)
- 10(n) Amendment to Elazar Rabbani's employment agreement. (9)
- 10(o) Amendment to Shahram Rabbani's employment agreement. (9)
- 10(p) Amendment to Barry Weiner's employment agreement.(9)
- 10(q) Lease Addendum (9)
- 21 Subsidiaries of the registrant:
Enzo Clinical Labs, Inc., a New York corporation.
Enzo Life Sciences, Inc., a New York corporation.
Enzo Therapeutics, Inc., a New York corporation.
- 23 Consent of Independent Auditors filed herewith.
- 99.1 Certification
- 99.2 Certification

- (1) The exhibits were filed as exhibits to the Company's Registration Statement on Form S-18 (File No. 2-67359) and are incorporated herein by reference.
- (2) This exhibit was filed as an exhibit to the Company's Form 10-K for the year ended July 31, 1981 and is incorporated herein by reference.
- (3) This exhibit was filed with the Company's Annual Report on Form 10-K for the year ended July 31, 1989 and is incorporated herein by reference.
- (4) This exhibit was filed with the Company's definitive proxy statement dated February 4, 1983 and is incorporated herein by reference.
- (5) This exhibit was filed with the Company's Annual Report on Form 10-K for the year ended July 31, 1994 and is incorporated herein by reference.

30

- (6) This exhibit was filed with the Company's Annual Report on Form 10-K for the year ended July 31, 1995 and is incorporated herein by reference.
- (7) This exhibit was filed with the Company's Annual Report on Form 10-K for the year ended July 31, 1996 or previously filed amendment thereto and is incorporated herein by reference.
- (8) This exhibit was filed with the Company's Registration Statement on Form S-8 (333-87153) and is incorporated herein by reference.
- (9) This exhibit was filed with the Company's Annual Report on Form 10-K for the year ended July 31, 2000 and is incorporated herein by reference.

(a) The Company's Current Reports on Form 8-K filed during the quarter ended July 31, 2002 -- none

(b) See Item 15(a)(3), above.

S I G N A T U R E S

- - - - -

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ENZO BIOCHEM, INC.

Date: October 29, 2002 By: /s/ Elazar Rabbani Ph.D.

Chairman of the Board

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: Elazar Rabbani Ph.D. October 29, 2002

Elazar Rabbani
Chairman of Board of Directors
(Principal Executive Officer)

By: Shahram K. Rabbani October 29, 2002

Shahram K. Rabbani,
Chief Operating Officer, Secretary
and Director (Principal Financial and
Accounting Officer)

By: Barry W. Weiner October 29, 2002

Barry W. Weiner,
President and Director

By: John B. Sias October 29, 2002

John B. Sias, Director

By: John J. Delucca October 29, 2002

John J. Delucca, Director

By: Irwin Gerson October 29, 2002

Irwin Gerson, Director

By: Stanford S. Warshawsky October 29, 2002

Stanford S. Warshawsky, Director

By: Melvin F. Lazar October 29, 2002

Melvin F. Lazar, Director

CERTIFICATION

I, Elazar Rabbani, Chairman and Chief Executive Officer certify that:

- 1. I have reviewed this annual report on Form 10-K of Enzo Biochem, Inc.;
- 2. Based on my knowledge, this annual report does not contain any untrue

statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report.

Date: October 29, 2002

/s/ Elazar Rabbani, Ph.D.

Elazar Rabbani, Ph.D.
Chairman and Chief Executive Officer

33

CERTIFICATION

I, Shahram K. Rabbani, Chief Operating Officer Secretary and Treasurer (Principal Financial Officer) certify that:

1. I have reviewed this annual report on Form 10-K of Enzo Biochem, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report.

Date: October 29, 2002

/s/ Shahram K. Rabbani

Shahram K. Rabbani
Chief Operating Officer, Secretary
and Treasurer
(Principal Financial Officer)

34

FORM 10-K, ITEM 14(a) (1) and (2)
ENZO BIOCHEM, INC.

LIST OF CONSOLIDATED FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE

The following consolidated financial statements and financial statement schedule of Enzo Biochem, Inc. are included in Item 14(a):

Report of Independent Auditors	F-2
Consolidated Balance Sheets -- July 31, 2002 and 2001	F-3
Consolidated Statements of Operations -- Years ended July 31, 2002, 2001 and 2000	F-4
Consolidated Statements of Stockholders' Equity -- Years ended July 31, 2002, 2001 and 2000	F-5
Consolidated Statements of Cash Flows -- Years ended July 31, 2002, 2001 and 2000	F-6
Notes to Consolidated Financial Statements	F-8

All other schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore have been omitted.

F-1

Report of Independent Auditors

Board of Directors and Stockholders
Enzo Biochem, Inc.

We have audited the accompanying consolidated balance sheets of Enzo Biochem, Inc. (the "Company") as of July 31, 2002 and 2001, and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended July 31, 2002. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Enzo Biochem, Inc. at July 31, 2002 and 2001 and the consolidated results of its operations and its cash flows for each of the three years in the period ended July 31, 2002, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/ Ernst & Young LLP

Melville, New York
October 4, 2002

F-2

ENZO BIOCHEM, INC.
CONSOLIDATED BALANCE SHEETS
JULY 31, 2002 and 2001

<TABLE>
<CAPTION>

ASSETS	2002	2001
	-----	-----
<S>	<C>	<C>
Current assets:		
Cash and cash equivalents	\$ 67,135,000	\$ 58,671,000
Accounts receivable, less allowance for doubtful accounts of \$4,445,000 in 2002 and \$6,526,000 in 2001	20,267,500	24,559,000
Inventories	4,190,200	2,019,800
Deferred taxes	777,500	1,708,500
Prepaid taxes	1,968,600	350,200
Other	1,491,000	1,132,300
	-----	-----
Total current assets	95,829,800	88,440,800
Property and equipment, at cost less accumulated depreciation and amortization	2,301,100	2,670,600
Cost in excess of fair value of net tangible assets acquired, less accumulated amortization of \$5,351,200 in 2002 and \$4,980,600 in 2001	7,452,000	7,822,700
Deferred patent costs, less accumulated amortization of \$6,347,100 in 2002 and \$5,553,400 in 2001	3,562,300	3,865,200
Other	146,200	131,800
	-----	-----

\$ 109,291,400 \$ 102,931,100
=====

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Trade accounts payable	\$ 1,512,300	\$ 2,039,500
Accrued legal fees	140,000	251,000
Accrued payroll	475,900	322,300
Other accrued expenses	734,400	734,400
	-----	-----
Total current liabilities	2,862,600	3,347,200
Deferred taxes	1,180,900	1,391,900
Deferred rent	514,700	675,000
Commitments and contingencies (Notes 5,6 and 9)		
Stockholders' equity:		
Preferred Stock, \$.01 par value; authorized 25,000,000 shares; no shares issued or outstanding Common Stock, \$.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 28,459,800 in 2002 and 27,080,100 in 2001	284,600	270,700
Additional paid-in capital	160,499,800	133,136,100
Accumulated deficit	(56,051,200)	(35,889,800)
	-----	-----
Total stockholders' equity	104,733,200	97,517,000
	-----	-----
	\$ 109,291,400	\$ 102,931,100
	=====	=====

</TABLE>

See accompanying notes.

F-3

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
Years ended July 31, 2002, 2001, and 2000

<TABLE>			
<CAPTION>			
	2002	2001	
2000	-----	-----	-

<S>	<C>	<C>	
<C>			
Revenues:			
Research product revenues	\$ 25,963,400	\$ 17,055,800	\$
11,371,500			
Clinical laboratory services	28,051,700	35,210,100	
31,475,100			
	-----	-----	-

42,846,600	54,015,100	52,265,900	
Costs and expenses:			
Cost of research product revenues	737,100	785,200	
339,700			
Cost of clinical laboratory services	10,109,500	10,498,400	
8,505,700			
Research and development expense	6,178,600	6,080,800	
5,430,900			
Selling expense	4,342,800	3,856,300	
3,240,800			
Provision for uncollectable accounts receivable	14,188,400	11,999,200	
11,294,000			
General and administrative expense	9,469,200	9,817,800	
8,951,700			
	-----	-----	-

37,762,800	45,025,600	43,037,700	

Income before interest income, and provision for taxes on income	8,989,500	9,228,200	
5,083,800			
Interest income	1,350,400	3,003,000	
2,584,600			
	-----	-----	-

Income before provision for taxes on income	10,339,900	12,231,200		
7,668,400				
Provision for taxes on income	(3,417,100)	(5,418,400)		
(1,043,700)				

Net income	\$ 6,922,800	\$ 6,812,800		\$
6,624,700				
=====				
Net income per common share:				
Basic	\$ 0.24	\$ 0.24		\$
0.24				
=====				
Diluted	\$ 0.24	\$ 0.23		\$
0.22				
=====				
Denominator for per share calculation:				
Basic	28,444,000	28,349,000		
27,927,000				
=====				
Diluted	29,322,000	29,531,000		
29,752,000				
=====				
</TABLE>				

See accompanying notes

F-4

ENZO BIOCHEM, INC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Years ended July 31, 2002, 2001 and 2000

<TABLE>				
<CAPTION>				
Total	Common	Common	Additional	
Stockholders'	Stock	Stock	Paid-in	Accumulated
Equity	Shares	Amount	Capital	Deficit
-----	-----	-----	-----	-----
<S>	<C>	<C>	<C>	<C>
<C>				
Balance at July 31, 1999	24,957,700	249,600	\$ 92,452,200	\$ (17,053,800)
\$ 75,648,000				
Net income for the year ended July 31, 2000	--	--	--	6,624,700
6,624,700				
Increase in common stock and paid-in capital due to exercise of stock options and warrants	621,600	6,100	4,120,100	--
4,126,200				
Issuance of stock for employee 401(k) plan	4,400	100	201,500	--
201,600				
Increase in paid-in capital due to issuance of warrants as compensation for services performed	--	--	100,000	--
100,000				
Tax benefit from stock options exercised	--	--	418,400	--
418,400				
Increase in paid-in capital due to stock issued for services performed	--	--	57,400	--
57,400				
-----	-----	-----	-----	-----
Balance at July 31, 2000	25,583,700	255,800	97,349,600	(10,429,100)

87,176,300

Net income for the year ended July 31, 2001 6,812,800	--	--	--	6,812,800
5% stock dividend (fair value on date declared) --	1,284,500	12,800	32,260,700	(32,273,500)
Increase in common stock and paid-in capital due to exercise of stock options 1,233,900	202,200	2,000	1,231,900	--
Issuance of stock for employee 401(k) plan 230,800	9,700	100	230,700	--
Tax benefit from stock options exercised 1,780,000	--	--	1,780,000	--
Increase in paid-in capital due to stock issued for services performed 283,200	--	--	283,200	--
-----	-----	-----	-----	-----
Balance at July 31, 2001 97,517,000	27,080,100	270,700	133,136,100	(35,889,800)
Net income for the year ended July 31, 2002 6,922,800				6,922,800
5% stock dividend (fair value on date declared) --	1,353,500	13,600	26,974,000	(26,987,600)
Payment of cash for fractional share for the 5% stock dividend (96,600)	--	--	--	(96,600)
Increase in common stock and pain-in capital due to exercise of stock options 128,000	15,200	200	127,800	
Tax benefit from stock options exercised 15,000	--	--	15,000	--
Issuance of stock for employee 401(k) plan 247,000	11,000	100	246,900	--
-----	-----	-----	-----	-----
Balance at July 31, 2002 \$ 104,733,200	28,459,800	\$ 284,600	\$ 160,499,800	\$ (56,051,200)
=====	=====	=====	=====	=====

</TABLE>

See accompanying notes

F-5

ENZO BIOCHEM, INC
CONSOLIDATED STATEMENT OF CASH FLOWS
Years ended July 31, 2002, 2001 and 2000

<TABLE>
<CAPTION>

	2002	2001	2000
	-----	-----	-----
<S>	<C>	<C>	<C>
Cash flows from operating activities:			
Net income	\$ 6,922,800	\$ 6,812,800	\$ 6,624,700
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization of property and equipment	989,900	1,131,200	832,100
Amortization of costs in excess of fair value of net tangible assets acquired	370,700	370,500	370,500
Amortization of deferred patent costs	793,600	750,600	722,400
Provision for uncollectible accounts receivable	14,188,400	11,999,200	11,294,000
Deferred income tax provision	720,000	2,003,000	255,400
Issuance of warrants as compensation for services performed	--	--	100,000
Issuance of stock as compensation for services performed	--	283,200	57,400
Issuance of stock for employee 401(k) plan	247,000	230,800	201,600
Tax benefit from stock options exercised	15,000	1,780,000	418,400

Deferred rent	(160,300)	(120,700)	(94,800)
Changes in operating assets and liabilities:			
Accounts receivable before provision for uncollectible amounts	(9,896,900)	(16,347,000)	(16,497,500)
Inventories	(2,170,400)	(220,900)	(372,200)
Prepaid taxes	(1,618,400)	(350,200)	--
Other current assets	(358,700)	(61,200)	160,600
Trade accounts payable and accrued expenses	(527,200)	504,000	246,200
Income taxes payable	--	(375,700)	75,700
Accrued legal fees	(111,000)	(413,600)	599,600
Accrued payroll	153,600	20,900	(62,600)
Total adjustments	2,635,300	1,184,100	(1,693,200)
Net cash provided by operating activities	9,558,100	7,996,900	4,931,500

</TABLE>

(Continued on following page.)

F-6

ENZO BIOCHEM, INC
CONSOLIDATED STATEMENT OF CASH FLOWS
Years ended July 31, 2002, 2001 and 2000

<TABLE>
<CAPTION>

	2002	2001	2000
	-----	-----	-----
<S>	<C>	<C>	<C>
Cash flows from investing activities:			
Capital expenditures	\$ (620,400)	\$ (1,013,900)	\$ (790,500)
Patent costs deferred	(490,700)	(567,900)	(458,400)
Security deposits	(14,400)	(5,000)	200
	-----	-----	-----
Net cash used by investing activities	(1,125,500)	(1,586,800)	(1,248,700)
	-----	-----	-----
Cash flows from financing activities:			
Payment for fractional shares of stock dividend	(96,600)	--	--
Proceeds from the exercise of stock options	128,000	1,233,900	4,126,200
	-----	-----	-----
Net cash provided by financing activities	31,400	1,233,900	4,126,200
	-----	-----	-----
Net increase in cash and cash equivalents	8,464,000	7,644,000	7,809,000
Cash and cash equivalents at the beginning of the year	58,671,000	51,027,000	43,218,000
	-----	-----	-----
Cash and cash equivalents at the end of the year	\$ 67,135,000	\$ 58,671,000	\$ 51,027,000
	=====	=====	=====

</TABLE>

See accompanying notes

F-7

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 1 - Business and summary of significant accounting policies

Business

Enzo Biochem, Inc. (the "Company") is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information. The Company is conducting research and development activities in the development of therapeutic

products based on the Company's technology platform of genetic modulation and immune modulation. The Company also operates a clinical reference laboratory that offers and provides diagnostic medical testing services to the health care community.

Summary of significant accounting policies

Principles of consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.

Cash and cash equivalents

The Company considers all highly liquid debt instruments purchased with maturities of three months or less to be cash equivalents.

Cash equivalents consist of short-term debt securities of domestic companies that the Company intends to hold to maturity that ranges from August 2002 to October 2002. The market values of these securities, as determined by quoted sources, aggregated \$64,089,300 and \$57,954,300 at July 31, 2002 and 2001, respectively, and approximated cost at the respective dates.

Concentration of credit risk

Approximately 69% and 82% at July 31, 2002 and 2001, respectively, of the Company's net accounts receivable relates to its clinical reference laboratory business, which operates in the New York Metropolitan area. The Company believes that the concentration of credit risk with respect to accounts receivable is limited due to the diversity of the Company's client base. However, the Company provides services to certain patients covered by various third-party payors, including the Federal Medicare program. Revenue, net of contractual allowances, from direct billings under the Federal Medicare program during the year ended July 31, 2001 was approximately 15% of the Company's total revenue. For the years ended July 31, 2002 and 2000 there were no payors with revenue, net of contractual allowances from direct billings, accounting for more than 10% of the Company's total revenues.

Research product revenue from one major distributor represented approximately 23% and 12% of the consolidated revenues in fiscal 2002 and 2001, respectively, under a non-exclusive distribution and supply agreement. At July 31, 2002 and 2001, 18% and 5% respectively, of the Company's net accounts receivable relate to amounts due from the one major distributor.

Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market.

Property and equipment

Property and equipment is stated at cost, and depreciated on the straight-line and accelerated methods over the estimated useful lives of the assets. Leasehold improvements are amortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter.

F-8

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 1 - Business and summary of significant accounting policies (Cont'd)

Amortization of intangible assets

The cost in excess of fair value of net tangible assets acquired is being amortized on the straight-line method over periods of fifteen to forty years.

Patent costs

The Company has filed applications for United States and foreign patents covering certain aspects of its technology. The costs incurred in filing such applications have been deferred and are amortized over the estimated useful lives of the patents beginning upon issue. Costs related to unsuccessful patent applications are expensed.

Revenue Recognition

Revenues from services from the clinical reference laboratory are recognized when services are provided. The Company's revenue is based on amounts billed or billable for services rendered, net of contractual adjustments and other

arrangements made with third-party payors to provide services at less than established billing rates. Revenues from research product sales are recognized when the products are shipped.

Reimbursement Contingencies

Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Shipping and Handling Costs

Research product revenue shipping and handling costs included in selling expense amounted to approximately \$325,000, \$279,000 and \$179,000 for fiscal years ended July 31, 2002, 2001 and 2000, respectively.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carryforwards and other items be reduced by a valuation allowance where it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

F-9

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 1 - Business and summary of significant accounting policies (Cont'd)

Impairment of Long-Lived Assets

The Company evaluates the requirement to recognize impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. Company management believes that no impairment to its long-lived assets has occurred.

Recently Issued Accounting Pronouncements

In July 2001, the Financial Accounting Standards Board Emerging Issues Task Force ("EITF") reached final consensus on EITF No. 00-25, "Vendor Income Statement Characterization of Consideration Paid to a Reseller of the Vendor's Products" ("EITF 00-25"), EITF 00-25 generally requires that consideration, including equity instruments, given to a customer be classified in a vendor's financial statements not as an expense, but as a reduction to revenue up to the amount of cumulative revenue recognized or to be recognized. In November 2001, the EITF reached consensus on EITF No. 01-09, "Accounting for Consideration Given by a Vendor to a Customer or Reseller of the Vendor's Products" ("EITF 01-09"). EITF 01-09 clarifies and modifies certain items discussed in EITF 00-25. We adopted these new standards in the quarter ended April 30, 2002.

The Company has certain non-exclusive distribution agreements, which provide for consideration to be paid to the distributors for the manufacture of certain products. Such consideration was previously included in cost of research product revenues. In accordance with EITF 00-25 and EITF 01-09, the Company has reclassified consideration provided to distributors under these non-exclusive distribution agreements as a reduction to research product revenues. The prior year and prior quarter comparative amounts have been reclassified to be consistent with the current year presentation. This change reflects a new reporting presentation only and did not affect the Company's gross profit or net

income as previously reported.

In June 2001, the FASB issued SFAS No. 141, "Business Combinations" and No. 142, "Goodwill and Other Intangible Assets". Statement 141 requires business combinations initiated after June 30, 2001 to be accounted for using the purchase method of accounting, and broadens the criteria for recording intangible assets separate from goodwill. SFAS No. 142 requires the discontinuance of amortization of goodwill and intangible assets with indefinite useful lives, subject to an annual review for impairment. Other intangible assets will continue to be amortized over their estimated useful lives. The Company will adopt the provisions of the statement on August 1, 2002. Although the Company is in the process of assessing the impact of adopting Statement No. 142, based upon its current level of goodwill and qualifying intangible assets, management expects the adoption to reduce its fiscal 2003 annualized amortization expense by approximately \$370,000.

In October 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, that is applicable to financial statements issued for fiscal years beginning after December 15, 2001, with transition provisions for certain matters. FASB's new rules on asset impairment supersede SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of, and provide a single accounting model for long-lived assets to be disposed of. Although retaining many of the fundamental recognition and measurement provisions of SFAS No. 121, the new rules significantly change the criteria that would have to be met to classify an asset as held-for-sale. The new rules supersede the provisions of Accounting Principals Board Opinion No. 30 ("APB No. 30") with regard to reporting the effects of a disposal of a segment of a business and require expected future operating losses from discontinued operations to be displayed in discontinued operations in the period in which the losses are incurred rather than as of the measurement date as presently required by APB No. 30. In addition, more dispositions will qualify for discontinued operations treatment in the income statement. The Company does not believe that the implementation of SFAS No. 144 will have any impact on its financial statements as of and for the year ending July 31, 2003.

F-10

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 1 - Business and summary of significant accounting policies (Cont'd)

Stock Dividend

The Company declared a 5% stock dividend on January 23, 2002 payable February 27, 2002 to shareholders of record as of February 2, 2002. The Company declared a 5% stock dividend on January 16, 2001 payable March 20, 2001 to shareholders of record as of February 27, 2001. The shares and per share data have been adjusted to retroactively reflect this stock dividend. The Company recorded a charge to accumulated deficit and a credit to common stock and additional paid-in capital in the amount of approximately \$26,988,000 in fiscal 2002 and \$32,274,000 in fiscal 2001, which reflects the fair value of the dividend on the date of declaration.

Net income per share

The Company reported basic and diluted earnings per share in accordance with SFAS No. 128, "Earnings Per Share" ("SFAS No. 128"). Basic earnings per share exclude any dilutive effects of options and warrants. Diluted earnings includes the dilutive effects of common stock equivalents such as stock options and warrants.

The following table sets forth the computation of basic and diluted net income per share pursuant to SFAS No. 128.

<TABLE>
<CAPTION>

	2002 ----	2001 ----	2000 ----
<S>	<C>	<C>	<C>
Numerator:			
Net income for numerator for basic and diluted net income per common share	\$ 6,922,800 =====	\$ 6,812,800 =====	\$ 6,624,700 =====
Denominator:			
Denominator for basic net income per common share-weighted-average shares	28,444,000	28,349,000	27,927,000

Effect of dilutive employee and

director stock options and warrants	878,000	1,183,000	1,825,000
	-----	-----	-----
Denominator for diluted net income per share-adjusted weighted-average shares	29,322,000	29,532,000	29,752,000
	=====	=====	=====
Basic net income per share	\$.24	\$.24	\$.24
	=====	=====	=====
Diluted net income per share	\$.24	\$.23	\$.22
	=====	=====	=====

F-11

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 2 - Supplemental disclosure for statement of cash flows

In the years ended July 31, 2002, 2001 and 2000, the Company paid cash for income taxes of approximately \$4,300,000, \$2,267,000 and \$294,000 respectively.

Note 3 - Inventories

At July 31, 2002 and 2001 inventories consist of:

	2002	2001
	----	----
<S>	<C>	<C>
Raw materials	\$119,500	\$85,700
Work in process	2,635,700	1,035,300
Finished products	1,435,000	898,800
	-----	-----
	\$4,190,200	\$2,019,800
	=====	=====

</TABLE>

Note 4 - Property and equipment

At July 31, 2002 and 2001 property and equipment consist of:

	2002	2001
	----	----
<S>	<C>	<C>
Laboratory machinery and equipment	\$1,702,600	\$1,471,200
Leasehold improvements	2,257,400	2,223,400
Office furniture and equipment	4,313,800	4,152,300
	-----	-----
	8,273,800	7,846,900
Accumulated depreciation and amortization	5,972,700	5,176,300
	-----	-----
	\$2,301,100	\$2,670,600
	=====	=====

</TABLE>

Note 5 - Lease obligations

Enzo Clinical Labs, Inc. ("Enzo Clinical Labs"), a wholly owned subsidiary of the Company, leases its office and laboratory space under several leases that expire between August 31, 2002 and November 30, 2004. Certain officers / directors of the Company own the building that Enzo Clinical Labs uses as its main facility. In addition to the minimum annual rentals of space, this lease is subject to an escalation clause. Rent expense under this lease approximated \$1,077,000, \$1,055,000 and \$1,017,000 in fiscal 2002, 2001 and 2000, respectively.

The Company has various other operating leases for office and laboratory space, which expire through fiscal 2006.

Total consolidated rent expense incurred by the Company during fiscal 2002, 2001 and 2000 was approximately \$1,710,000, \$1,631,000 and \$1,547,000 respectively. Minimum annual rentals under operating lease commitments for fiscal years ending

July 31 are as follows:

2003	\$1,504,000
2004	1,204,000
2005	372,000
2006	17,000

	\$3,097,000
	=====

F-12

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 6 - Litigation

Patent Infringement

In June 1999, the Company filed suit in the United States District Court for the Southern District of New York against Gen-Probe Incorporated, Chugai Pharma U.S.A., Inc., Chugai Pharmaceutical Co., Ltd., bioMerieux, Inc., bioMerieux SA, and Becton Dickinson and Company, charging them with infringing the Company's U.S. Patent 4,900,659, which concerns probes for the detection of the bacteria that causes gonorrhea. On January 26, 2001, the court granted the defendants' motion for summary judgment that the Company's patent is invalid. On July 15, 2002, the Court of Appeals for the Federal Circuit reversed the judgment of invalidity and remanded the case to the district court for further proceedings. The proceedings on remand are at an early stage. There can be no assurance that the Company will be successful in these proceedings. However, even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact.

On March 6, 2002, the Company was named, along with certain of its officers and directors among others, in a complaint entitled Lawrence F. Glaser and Maureen Glaser, individually and on behalf of Kimberly, Erin, Hannah, and Benjamin Glaser v. Hyman Gross, Barry Weiner, Enzo Biochemical Inc., Elazar Rabbani, Shahram Rabbani, John Delucca, Dena Engelhardt, Richard Keating, Doug Yeats, and Docs I-50, in the U.S. District Court for the Eastern District of Virginia. The complaint was filed by an investor in the Company who has filed for bankruptcy protection and his family. The complaint alleges securities and common law fraud and breach of fiduciary duty and seeks in excess of \$150 million in damages. On August 22, 2002, the complaint was voluntarily dismissed, however a new substantially similar complaint was filed at the same time. On October 21, 2002, the Company and the other defendants filed a motion to dismiss the complaint, this motion is pending before the Court.

In March 2002, Enzo Life Sciences, a subsidiary of the Company, filed suit in the United States District Court for the District of Delaware against Digene Corp., charging it with infringing the Company's U.S. Patent No. 6,221,581 B1, which concerns a novel process for detecting nucleic acids of interest. On May 31, 2002, Digene filed counterclaims in that suit against Enzo Life Sciences and the Company, including business tort counterclaims relating to the '581 patent. The case is at an early stage. There can be no assurance that the Company and Enzo Life Sciences will be successful in these proceedings. However, even if Enzo Life Sciences is not successful in its patent infringement suit, management does not believe that there will be a significant adverse monetary impact. With respect to Digene's counterclaims, the Company and Enzo Life Sciences believe them to be without merit and intend to defend themselves vigorously.

In October 2002, the Company filed suit in the United States District Court of the Southern District of New York against Amersham plc, Amersham Biosciences, Perkin Elmer, Inc., Perkin Elmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc. and Orchid Biosciences, Inc. The counts set forth in the suit are for breach of contract; patent infringement; unfair competition under state law; unfair competition under federal law; tortious interference with business relations; and fraud in the inducement of contract. The complaint alleges that these counts arise out of the defendants' breach of distributorship agreements with the Company concerning labeled nucleotide products and technology, and the defendants' infringement of patents covering the same. There can be no assurance that the Company will be successful in this litigation. However, even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact.

Note 7 - Income taxes

The tax provision is calculated under the provisions of SFAS No. 109.

<TABLE>
<CAPTION>

	2002 ----	2001 ----	2000 ----
<S>	<C>	<C>	<C>
Current			
Federal	\$2,211,600	\$2,783,400	\$616,300
State and local	485,500	632,000	172,000
Deferred	720,000	2,003,000	255,400
	-----	-----	-----
Provision for income taxes	\$3,417,100	\$5,418,400	\$1,043,700
	=====	=====	=====

</TABLE>

Current Federal income taxes provided for in fiscal 2002 and 2001 are based on regular tax, and in fiscal 2000 are based on the alternative minimum tax method.

F-13

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 7 - Income taxes (Cont'd)

Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferred income taxes are as follows:

<TABLE>
<CAPTION>

	2002 ----	2001 ----
<S>	<C>	<C>
Deferred tax assets:		
Provision for uncollectible accounts	\$787,400	\$1,612,900
Receivable		
Alternative minimum tax credits	---	105,800
Other	198,400	293,200
	-----	-----
	985,800	2,011,900
Deferred tax liability:		
Deferred patent costs	(1,389,200)	(1,695,300)
	-----	-----
Net deferred tax (liability) asset	\$ (403,400)	\$ 316,600
	=====	=====

</TABLE>

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax asset will be realized. The ultimate realization of the deferred tax asset is dependent upon the generation of future taxable income. Management considers scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies that can be implemented by the Company in making this assessment.

The provision for income taxes were at rates different from U.S. federal statutory rates for the following reasons:

<TABLE>
<CAPTION>

	2002 ----	2001 ----	2000 ----
<S>	<C>	<C>	<C>
Federal statutory rate	34%	34%	34%
Expenses not deductible for income tax return purposes	2%	1%	4%
State income taxes, net of federal tax deduction	5%	9%	9%
Benefit of extraterritorial income exclusion	(4%)	---	---
Benefit of tax credits	(4%)	---	---
Change in deferred tax asset valuation reserve and benefits recognized from net operating losses	---	---	(33%)
	-----	-----	-----
	33%	44%	14%
	=====	=====	=====

</TABLE>

Note 8 - Stock options

The Company follows the disclosure provisions of SFAS No. 123. SFAS No. 123 defines a fair value method of accounting for the issuance of stock options and other equity instruments. Under the fair value method, compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. Pursuant to SFAS No. 123, companies are encouraged, but are not required, to adopt the fair value method of accounting for employee stock-based transactions. Companies are also permitted to continue to account for such transactions under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25"), but are required to disclose in a note to the consolidated financial statements proforma net income and per share amounts as if the Company had applied the new method of accounting. SFAS No. 123 also requires increased disclosures for stock-based compensation arrangements.

The Company has elected to comply with APB 25, in accounting for its stock options because, as discussed below, the alternative fair value accounting provided for under SFAS No. 123, requires use of option valuation models, which were not developed for use in valuing employee stock options. Under APB 25, because the exercise price of the Company's employee stock options equals or exceeds the market price of the underlying stock on the date of grant, no compensation expense is recognized.

The Company has an incentive stock option plan and a restricted stock incentive plan, as described below.

F-14

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 8 - Stock options (Cont'd)

Incentive stock option plan

The Company has an incentive stock option plan ("1983 plan") under which the Company may grant options for up to 1,148,654 shares of common stock. No additional options may be granted under the 1983 plan. The exercise price of options granted under such plan is equal to or greater than fair market value of the common stock on the date of grant. The Company has stock option plans ("1993 plan" and "1994 plan") under which the Company may grant options for up to 1,914,422 shares (1993 plan) and for up to 1,212,467 shares (1994 plan) of common stock. No additional options may be granted under the 1993 plan or the 1994 plan. In fiscal 1999, the Company set up a new incentive stock option plan ("1999 plan") under which the Company may grant up to 2,097,375 shares of common stock. The options granted pursuant to the plans may be either incentive stock options or nonstatutory options. To date, the Company has only granted incentive stock options under these plans.

A summary of the information pursuant to the Company's stock options plans for the years ended July 31, 2002, 2001 and 2000 under SFAS No. 123 is as follows:

<TABLE>
<CAPTION>

	2002		2001		2000	
Average	Weighted - Average		Weighted - Average		Weighted -	
Price	Options	Exercise Price	Options	Exercise Price	Options	Exercise
	-----	-----	-----	-----	-----	-----
<S>	<C>	<C>	<C>	<C>	<C>	<C>
Outstanding at beginning of year	2,598,272	\$ 9.75	2,420,346	\$ 9.14	2,977,785	\$ 8.14
Granted	23,625	22.27	400,312	14.25	92,610	23.02
Exercised	(15,990)	8.08	(218,258)	5.40	(630,244)	6.38
Terminated	(28,673)	11.78	(4,128)	14.23	(19,805)	10.82
	-----		-----		-----	
Outstanding at end of year	2,577,234	\$ 10.34	2,598,272	\$ 10.23	2,420,346	\$ 9.14
	=====		=====		=====	
Exercisable at end of year	2,084,270	\$ 9.71	1,786,467	\$ 9.28	1,713,797	\$ 8.54

Weighted average fair value of options granted during year	\$ 22.27	\$ 14.25	\$ 17.68
--	----------	----------	----------

</TABLE>

The following table summarizes information for stock options outstanding at July 31, 2002:

<TABLE>
<CAPTION>

Exercisable	Options Outstanding			Options	
	Range of Weighted-Average Exercise prices	Shares	Weighted-Average Remaining Contractual Life	Weighted-Average Exercise Price	Shares
<S>		<C>	<C>	<C>	<C>
\$3.53 - 5.29	6,382	.19 years	\$3.53	6,382	
\$3.53 - 8.96	1,213,785	3.22 years	7.32	1,143,620	
7.39 - 13.78	1,170,781	6.32 years	11.75	826,816	
11.47 - 21.38	113,836	6.03 years	17.67	78,708	
16.89 - 33.41	55,912	4.99 years	23.62	12,206	
23.86 - 39.74	16,538	7.46 years	39.74	16,538	
	2,577,234			2,084,270	

</TABLE>

F-15

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 8 - Stock options (cont'd)

Incentive stock options generally become exercisable at 25% per year after one year and expire ten years after the date of grant.

Pro-forma information regarding net income and net income per share is required by SFAS No. 123, and has been determined as if the Company had accounted for its stock options under the fair value method of that statement. The fair value for these options was estimated at the date of grant using a Black-Sholes option pricing model with the following assumptions: risk free interest rate ranging from 3.45% to 6.88%; no dividend yield; volatility factor of the expected market price of the Company's common stock of .78, .80 and .80 for grants during fiscal year ended July 31, 2002, 2001 and 2000, respectively and a weighted-average expected life of the options of 7 years at July 31, 2002, 2001 and 2000.

The Black-Sholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

For purposes of pro forma disclosures, the estimated fair value of the options is amortized to expense over the options' vesting period. The Company's pro forma information is as follows:

<TABLE>
<CAPTION>

2002	2001	2000
------	------	------

<S>	<C>	<C>	<C>
Pro forma net income:	\$4,325,000	\$4,398,000	\$4,278,000
Pro forma net income per share:			
Basic	\$.15	\$.16	\$.15
Diluted	\$.15	\$.15	\$.14

The SFAS No. 123 method of accounting has not been applied to options granted prior to August 1, 1995. As a result, the pro forma compensation cost may not be representative of that to be expected in future years.

Restricted stock incentive plan

The Company has a restricted stock incentive plan whereby the Company may award up to 255,256 shares of its common stock. Under the terms of the plan, any shares issued are restricted in regard to sales and transfers for a period of five years after award. Such restrictions begin to expire at 25% per year after the second year of ownership. As of July 31, 2002, the Company has not awarded any shares of common stock under this plan.

As of July 31, 2002, the Company has reserved 5,563,238 shares under the arrangements described above.

Note 9 - Commitments

The company has an exclusive licensing agreement to an invention covered by licensed patents. Under this agreement, the Company is required to make certain minimum royalty payments of \$200,000 per year through the life of the patents.

F-16

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2002, 2001 and 2000

Note 10 - Employee benefit plan

The Company has a qualified Salary Reduction Profit Sharing Plan (the "Plan") for eligible employees under Section 401(k) of the Internal Revenue Code. The Plan provides for voluntary employee contributions through salary reduction and voluntary employer contributions at the discretion of the Company. For the years ended July 31, 2002, 2001 and 2000, the Company has authorized employer contributions of 50% of the employees' contribution up to 10% of the employees' compensation in Enzo Biochem, Inc. common stock. The 401(k) employer contributions expense was \$247,000, \$230,800 and \$201,600 in fiscal years 2002, 2001 and 2000, respectively.

Note 11 - Quarterly financial data (unaudited)

Unaudited quarterly financial data (in thousands, except per share amounts) for fiscal 2002 and 2001 is summarized as follows:

<TABLE>
<CAPTION>

	Three Months Ended			
	October 31, 2001	January 31, 2002	April 30, 2002	July
31, 2002	-----	-----	-----	--
<S>	<C>	<C>	<C>	<C>
Revenues \$13,781	\$13,386	\$11,827	\$15,021	
Gross profit 11,360	10,543	8,650	12,616	
Income before provision for taxes on income 1,599	3,143	1,307	4,291	
Net income \$1,725	\$1,825	\$822	\$2,551	
	=====	=====	=====	

	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Operating revenues:							
Research product revenues	\$25,963	\$17,056	\$11,372	---	---	---	---
Clinical laboratory services	---	---	---	\$28,052	\$35,210	\$31,475	---
Cost and expenses:							
Cost of research product revenues	737	785	340	---	---	---	---
Cost of clinical laboratory services	---	---	---	10,110	10,498	8,506	---
Research and development expense	6,179	6,081	5,431	---	---	---	---
Depreciation and amortization	923	856	814	1,231	1,397	1,111	---
Other costs and expenses	1,520	1,044	947	20,467	19,520	18,138	3,858
Interest income	---	---	---	---	---	---	\$1,350
Income (loss) before provision for taxes on income	\$16,604	\$8,290	\$3,840	\$(3,756)	\$3,795	\$3,720	(\$2,508)

<CAPTION>

	Consolidated Fiscal Year Ended July 31,		
	2002	2001	2000
Operating revenues:			
Research product revenues	\$25,963	\$17,056	\$11,372
Clinical laboratory services	\$28,052	35,210	31,475
Cost and expenses:			
Cost of research product revenues	737	785	340
Cost of clinical laboratory services	10,110	10,498	8,506
Research and development expense	6,179	6,081	5,431
Depreciation and amortization	2,154	2,253	1,925
Other costs and expenses	25,845	23,421	21,562
Interest income	1,350	3,003	2,585
Income (loss) before provision for taxes on income	\$10,340	\$12,231	\$7,668

</TABLE>

The Company's reportable segments are determined based on the services they performed and the products they sell, not on the geographic area in which they operate. The Company's clinical reference laboratories segment operates 100% in the United States with all revenue derived from this country. The research and development segment earns revenue both in the United States and foreign countries. The following is a summary of research and development revenues attributable to customers located in the United States and foreign countries:

	2002	2001	2000
United States	\$21,431	\$14,257	\$8,076
Foreign Countries	4,532	2,799	3,296
	\$25,963	\$17,056	\$11,372

ENZO BIOCHEM, INC.
SCHEDULE II - VALUATION
AND QUALIFYING ACCOUNTS
Years ended July 31, 2002, 2001 and 2000

<TABLE>
<CAPTION>

at Description period	Balance at Beginning of period	Charged (credited) to costs and expenses	Additions		Balance end of
			Charged to other accounts	(Additions) Deductions	
2002					
<S>	<C>	<C>	<C>	<C>	<C>
Allowance for doubtful accounts receivable 4,445,000	\$6,526,000	\$14,188,000	--	16,269,000 (1)	
2001					
Allowance for doubtful accounts receivable \$6,526,000	\$5,890,000	\$11,999,000	--	\$11,363,000 (1)	
2000					
Allowance for doubtful accounts receivable \$5,890,000	\$6,027,000	\$11,294,000	--	\$11,431,000 (1)	
Allowance for deferred tax valuation --	\$2,570,000	\$(2,570,000)	--	--	

</TABLE>

(1) Write-off of uncollectible accounts receivable.

Consent of Independent Auditors

We consent to the incorporation by reference in the Registration Statements (Forms S-3, No. 333-15533, 33-58736, 33-60229, 33-78760, 33-72170, 33-68542) and (Forms S-8 No. 33-45348, 33-75466, 33-88826, 333-87153 and 333-89308) of Enzo Biochem, Inc. and in the related Prospectus of our report dated October 4, 2002, with respect to the consolidated financial statements and schedule of Enzo Biochem, Inc. included in this Annual Report (Form 10-K) for the fiscal year ended July 31, 2002.

/s/ Ernst & Young LLP

Melville, New York
October 28, 2002

CERTIFICATE PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries ("the Company") on Form 10-K for the year ended July 31, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Elazar Rabbani, Ph.D.

Elazar Rabbani, Ph.D.
Chief Executive Officer

October 29, 2002

CERTIFICATE PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries ("the Company") on Form 10-K for the year ended July 31, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Shahram K. Rabbani, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Shahram K. Rabbani

Shahram K. Rabbani
Principal Financial Officer

October 29, 2002